annual report roche founded digalen first standardised heart medication roche present nine countries three continents alice keller manager roche japan first female executive first company massproduce vitamins rimifon first treatment tuberculosis first leap diagnostics cobas bio first automated lab device roferona genetically engineered cancer therapeutic roche acquires pcr technology roche launches phelophepa mobile health clinics south africa first protease inhibitor aids mabtherarituxan worlds first targeted antibody cancer drug roche acquires boehringer mannheim alliance chugai pharmaceutical japan first childrens walk global childrens charities full integration biotech pioneer genentech cobas hpv test detect cervical cancer kadcyla antibodydrug conjugate herpositive breast cancer acquisition foundation medicine ocrevus monoclonal antibody multiple sclerosis acquisition flatiron health covid tests years making difference lives millions day breakthrough medicines innovative diagnostic solutions improve lives countless people worldwide year legacy also promise future year anniversary see every reason celebrate life celebration whether creating new memories resonate years pausing reflect precious moments past celebrated history culture enduring purpose guides roches next years towards sustainable healthy future celebrated lifejoint interview andr hoffmann jrg duschmal roche stability longterm thinking andr hoffmann jrg duschmal members roches founding families board directors occasion year anniversary share thoughts past present future company ancestor fritz hoffmann founded roche representing fourth fifth years ago milestone generation founding families anniversary mean describe role family hoffmann feel extremely proud great company structure grandfather fritz hoffmann many hoffmann longterm family ownership family members would pleased see helps provide stability company roche evolved years anniversary establishing active partnership management important milestone company board companys longterm success thinks sustainably longterm exist forever think structure triangle unites family board directors j duschmal looking back rich history corporate executive committee corporate years able shape next chapter executive committee leads company roche new member board directors board directors sets strategy monitors course great privilege something implementation owner ensures much looking forward roche always longterm direction separation control played important part life execution important see role family representative privilege also mean exactly major responsibility j duschmal since early childhood roche present life always feeling j duschmal fact family strongly connected taught part success story roche lasting bond family beginning fills pride roche continue company corresponding responsibility count rely us committed loyal since grew basel roche course also majority shareholders want pass healthy visually present city sustainable company next generation think really longterm vision andr grew camargue france bring company able boldly roche also play big role invest areas pay upbringing even years certainly big advantage hoffmann bit different stable family ownership bring remember father always spoke proudly roche didnt grow switzerland ways family didnt constant connection company involved decisionmaking back started realising actual importance hoffmann family engaged impact company teenage years selection members board directors part governance company sustainability something alongside important us values goals business activities like marketing sales company represented individuals truly sustainable every action board something pay attention engage must defined terms durability selection process traditionally success defined positive cash flows simple measuring family deal internal financial consequence business activity fails differences affect important forward measure social human environmental looking business decisions impact action use hoffmann us wellbeing natural social human capital ways company always common driver create sustainable longterm value starts share values joint responsibility constantly acting eye greater also keeps us together family value impact society connect bring stability years roche thinking tomorrow part history legacy equally important j duschmal family make priority future listen one another always focus important thing longterm success jrg perspective sustainability roche helps finding common ground j duschmal agree andrs points andr says benefits company additionally scientist associate sustainability roches strength innovation powerhouse core roches success order successful long term j duschmal roche managed reinvent innovate frontier scientific original idea knowledge benefit patients often produce medicines highest quality matter taking certain risks today might today roche one largest biotech appear lucrative short term create diagnostics companies world owe sustainable value long term success innovative research many partnerships entered researcher roche foresight courage continue time future j duschmal wonderful time experience eyeopener importance hoffmann success many teams science great things achieved great talents around world contribute able experience firsthand everyday done sustainable culture values company mean everyday way kept societal patient needs work great personal commitment focus perseverance takes advance research idea therapy save lives talking sustainable ways known sustainability ambassador andr makes roche culture special believe important hoffmann special people topic roche interact hoffmann start let state us driven passion make difference obvious future sustainable patients also shape future humanity continue thrive external partnerships coincidence think behave sustainably partner choice manyjoint interview andr hoffmann jrg duschmal roche j duschmal convinced hoffmann position experienced roches values lived every family invested day addition company commitment company long term assets essentially every employee knows follow science consist roche shares gives us shapes us proud privilege responsibilities ownership part company see ownership passive role active one commit look future see roches success real way alongside roche years employees work roche j duschmal expect focus dont feel like investor see even prevention personalised someone prepares company therapies also likely great next generation advances therapeutic areas great medical need neurological diseases j duschmal see similarly future think industry collaboration shares give us opportunity influence healthcare stakeholders must succeed company value share package improving access healthcare also believe would relevant us sell better availability data positively committed longterm success change research make impactful roche hoffmann hopefully roche company still headquarters successful today also task basel ever discuss moving hand healthy company next another location generation family hoffmann even though active countries today roots success mean switzerland happy basel hoffmann roche creating better location also research future millions people greatest conducted end success driving medical innovation open new innovation centre stateoftheart requires us take bold risks requires lab facilities looking forward visiting room manoeuvre enough finished profits invest sustainably focus profit maximisation j duschmal research basel right society value profit great network partners support us generating activities delighted witness long headquarters location supports everyday acts generosity kindness us bringing breakthrough innovations patients lead invoice sent acting right place graciously altruistic way one things makes us human lets try theme roches year anniversary forget kind thinking celebrate life celebrate life continue sustainable organisation j duschmal probably enjoying nice dinner years come family friends part wealthy hoffmann celebrate life successful family significance harmony nature wish usour purpose roche patients need next believe urgent deliver medical solutions right even develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world rochecontents roche contents shareholder letters reporting strategy diagnostics pharmaceuticals personalised healthcare access healthcare people culture environment community engagement business ethics business performance corporate governance remuneration report arrochecomshareholder letters roche shareholder letterschairmans shareholder letter roche dear shareholders since founding years ago roche milestones companys history worked improve health lives countless include early adoption biotechnology people world anniversary time almost nobody believed used year exception discovery monoclonal antibodies revolutionise employees partners developed cancer therapy pcr technology manufactured provided global access also pioneers molecular diagnostics stateoftheart diagnostics treatments serious diseases including covid roche innovation always efforts guided pioneering spirit identifying seizing opportunities characterised roche since founding remain future well digitalisation sincere thanks substantially increased pace companys transformation since became chairman covid pandemic dominated world board directors view health data events past two years medical practice opportunity pursue first time known yet unknown pathogens ongoing development personalised thus suddenly spread presented us even effective medicine time major challenges certainly analysis data supports laboratory last roche established effect research development new clinical trial pandemic fritz hoffmann taken concepts enables us accelerate approval position merchant hamburg summer procedures innovative therapies make cholera broke result available patients faster experience decided set industrial pharmaceutical company return basel going forward want use digitalisation aim provide large quantities effective achieve medical progress lower cost medicines uniform quality still therefore increase investment revolutionary concept time research development even though rd expenditure billion swiss francs years since establishment last year already exceeds roche repeatedly found courage healthcare company worldwide reinvent guided scientific progress recently reminded visit poland one roches particular strengths long roche opened branch back early term mindset privilege great deal last century impact researchers stability afforded us founding leo sternbach polish chemist enormous families would like express discovered benzodiazepines valium sincere thanks thinking sustainably librium become indispensable dna delighted motivated treatment anxiety insomnia nervousness selected dow jones roche still actively involved field sustainability indices one worlds neuroscience ocrevus treatment sustainable companies healthcare sector multiple sclerosis one soughtafter received recognition medicinal products thirteenth year unless otherwise stated growth rates report constant exchange rates cer average last year achieved additional milestone behalf board directors wish extraordinary general meeting end thank sincerely valuable contributions november approved buyback roches success roche bearer shares held novartis past years nearunanimous vote confident delighted propose dr jemilah mahmood billion swiss francs transaction doctor malaysia new member best strategic financial interests roche board directors great expertise investors restores full control field public health especially less developed strategic decisions without requiring us restrict regions world particular experience operative scope enable help roche make medicines diagnostic products even accessible strong product pipeline severin schwan people world describes detail letter financial figures group sales rose roche special focused sciencedriven billion swiss francs net income amounted innovation committed sustainability rooted billion swiss francs confirm roche switzerland open world right path light good performance board directors proposing dividend would like thank shareholders increase swiss francs per share non confidence loyalty voting equity security subject approval th consecutive dividend increase finally would like draw attention number changes roche board directors ten years member board directors paul bulcke decided stand dr christoph franz reelection general meeting chairman roche board directors december julie brown b e g bernard poussot c e g dr jrg duschmal representative shareholder group pooled voting rights b e g dr christoph franz chairman c e g prof dr hans clevers e g andr hoffmann vicechairman representative corporate governance sustainability committee shareholder group pooled voting rights c e g b audit committee dr severin schwan f c remuneration committee dr claudia suessmuth dyckerhoff e g chairmansnomination committee dr patrick frost b e g e nonexecutive director paul bulcke b e g f executive director anita hauser e g g independent member board directors prof dr richard p lifton c e g committee chairpersonboard directors roche shareholder letter ceo roche group roche dear shareholders improving peoples lives delivering medical demand effective treatments also innovations roche extremely high nervous system disorders years many medicines recent study data highlighted benefits developed decades ago still greatly benefiting ocrevus multiple sclerosis enspryng millions people today world health nmosd rare disease affecting central organizations model list essential medicines nervous system roche researching includes products record high developing dozen medicines treat neurological disorders including huntingtons future roches success based parkinsons alzheimers disease medical innovations despite successes still great need better therapies diagnostics worldleading portfolio many areas cancer dementia diagnostic solutions covid infections far beyond covid need working tirelessly since start pandemic effective treatments give people serious constantly expand range coronavirus diseases better life even cure need tests roche investing significant amounts precision diagnostics find cause establishing additional production capacity disease treat earliest possible meet continued high demand routine stage preventive diagnostics also gaining diagnostics increasing significance innovative diagnostics essential prevention looking ahead pleased continued early detection treatment decisions infectious high demand newly launched medicines diseases cancer serious conditions diagnostic tests well development product pipelines divisions expanded leading position area infectious diseases two last year continued make significant targeted acquisitions tib molbiol brought progress patients tecentriq became first substantial number tests broad portfolio cancer immunotherapy people earlystage molecular diagnostic solutions acquisition lung cancer approved many means genmark strengthens commitment hope cure polivy first medicine combating antibiotic resistance also launched years significantly improve outcomes three molecular pcr diagnostic test panels form aggressive blood cancer simultaneously detect common respiratory pathogens one patient sample ophthalmology granted regulatory approval susvimo innovative eye implant accurate diagnosis enables patients receive susvimo offers alternative monthly injections appropriate treatment prevents eyes thus make lives people exposed antibiotics might wet agerelated macular degeneration great respond however diagnostic tests play deal easier furthermore applied regulatory crucial role combating infectious approval vabysmo first new class diseases also help prevent diseases eye medicines targets two key signalling cervical cancer hepatitis crelated pathways cause retinal diseases liver cancer digitalisation area roche investing digital products specific apps also heavily becoming ever significant delivering ever better support monitoring factor medical progress roche embarked treatment therapeutic areas strategic partnerships foundation medicine neurology ophthalmology fmi flatiron health several years ago recognise combining highquality genomics everything achieved would realworld data patient data clinical possible without people work practice delivers completely new approaches roche worldwide would like thank data sets available sufficient quantity exemplary dedication commitment quality represent enormous potential despite challenges pandemic going forward already within grasp today people research development production crucial driver efforts advance distribution support functions around personalised healthcare focus world working tirelessly ensure patients making significant improvement cancer continue receive lifesaving medicines patients accelerating discovery diagnostics development new cancer medicines would also like thank shareholders treat cancer effectively first necessary trust placed company understand molecular mechanisms underlying disease autumn roche therefore partnered fmi launch genome profiling kit personalised cancer research kit first enable researchers use fmis comprehensive genomic profiling assay laboratories digital solutions enable recording structuring analysing patients data supporting clinical dr severin schwan decisionmaking driving forward research ceo roche group roche corporate executive committee december dr alan hippe chief financial information officer claudia bckstiegel general counsel dr aviv regev head genentech research early development gred dr william pao head roche pharma research early development pred dr severin schwan ceo roche group cristina wilbur chief people officer bill anderson ceo roche pharmaceuticals barbara schdler head group communications dr james h sabry global head pharma partnering dr thomas schinecker ceo roche diagnostics member enlarged corporate executive committeecorporate executive committee roche reporting strategy roche reporting strategy reporting approach roche committed transparent reporting endeavour drive economic social environmental performance diligence financial performance reporting scope boundaries risk advisory team overall process financial nonfinancial reporting consists reviewed audit committee board annual report finance report directors reviewed externally appropriate online report contains annual financial risk management embedded levels statements consolidated financial statements roche group pharmaceuticals diagnostics nonfinancial performance indicators covers divisions global functions conduct formal regions divisions roche group risk opportunity assessment process least january december financial year must develop response plans reporting scope defined outlined material risks opportunities finance report significant changes scope compared read corporate governance gri standards materiality also identify longterm business sustainability followed gri global reporting trends associated risks opportunities initiative g guidelines since transitioned annual basis integrate gri standards using gri existing group risk management process guidelines disclose critical impacts year emerging trends including associated risks activities environment society opportunities identified internal economy respect conducted external sources first materiality analysis corporate level conducted based findings sustainability steering second global materiality assessment including committee prioritises selects top business expert interviews feedback sustainability trends among identified trends stakeholders results assessment healthcare evolution societal crises featured pages report also published website see link un sustainable development goals support united nations sustainable development goals sdgs within sphere risk management corporate business strategy contribute risk management policy sets roches number sdgs particularly approach identifying analysing managing pleased see dedicated goal health sdg reporting internal external risks goal closely connected achievement opportunities consolidated group risk report universal health coverage goes hand covers material risks opportunities hand better access quality essential discussed annually corporate executive medicines diagnostics fits perfectly material topic committee reviewed board directors vision improve save lives since personalised healthcare effectiveness group risk management sdgs integral part process regularly monitored group annual reporting report arrochecom rochecomarepdf rochecomfbepdf risk management rochecomriskmanagement key performance indicators rochecomperformanceour reporting approach roche examples contribution un goals listed un sdg webpage see link business sustainability trends mapped material topics featured healthcare evolution signatory un global compact ungc healthcare moving towards continuum care approach including commit integrate universal principles prevention treatment cure offering wider range products areas human rights labour environment service solutions unique opportunity accelerate delivery anticorruption business strategy truly integrated patientcentric personalised healthcare solutions culture daily operations report example introduced navify symptom tracker results achieved year publish first offers remote monitoring covid symptoms also developing communication progress first quarter cloudenabled integration engines support digital health ecosystems mobile apps patients healthcare professionals like mysugr app monitor manage diabetes smartphone risks external assurance opportunities associated new digital health arena nonfinancial reporting verified assessed managed group risk management process pricewaterhousecoopers ag pwc independent third party focused materiality determination societal crises process design sustainability risks ineffective social models limited economic educational opportunities determination process prospects likely lead dissolution societal solidarity figures areas safety security health exacerbate mental health deterioration youth disillusionment environmental protection people contributions consider role drive publicprivate partnerships since result roches strengthened initiatives working collaboration governments healthcare control framework review procedures providers tackle risks also see opportunity demonstrate reporting aspects figures related employer choice acknowledging importance grants donations sponsorships healthcare health wellbeing employees provide various offerings patient organisations subject support employees families flexible working arrangements reasonable assurance performed pwc parental leave men women childcare facilities figure disclosed nonfinancial reporting provisions help employees combine career family roles key performance indicators webpage including unpaidleave options people needing care elderly relative pwc assurance report see independent assurance report materiality impact purpose patients need next identify meet needs every day must sustainable succeed sustainability built business strategy part everyones job roche approach holistic integrates three aim reduce dimensions sustainability greenhouse gas emissions absolute zero society contribute better partnering suppliers reduce tomorrow emissions mutual benefit environment minimise impact nature economy economy invest medical advances business must meet needs patients create jobs ensure livelihoods continue creating quality jobs provide people families secure livelihoods mean us roche earning competitive returns investors every day promoting innovation translating science pioneering medicines society diagnostics help patients live longer contribute better society enabling better productive lives enabling right treatment right patient right support contribute time right value developing local economies new medicines ways diagnosing disease gaining insights data commitment described strategy setup designed expand access innovations help innovation autonomous research patients live longer better lives development centres alliances comes deep respect human external partners foster diversity scientific rights everyone reach especially patients approaches agility roche operates business partners suppliers local communities countries local teams implement course colleagues around world strategy measure performance emphasise employee safety health report stakeholders progress towards development promoting diversity goals set inclusion integrity mutual respect equal opportunities materiality assessment stakeholder engagement environment engaging stakeholders essential respect healthy planet build trust understanding environment always priority expectations embedding feedback founding families company strategy daily business able committed halving environmental jointly address common issues develop impact operations products longterm solutions sustainability rochecomsustainability materiality rochecommateriality stakeholder engagement rochecomstakeholderengagement key performance indicators rochecomperformance contribution un sdgs rochecomunsdgsmateriality impact roche order identify topics particularly relevant roche stakeholders society large deliver lasting shared value conducted indepth materiality assessment society environment corporate level among key stakeholders approach materiality sustainability assessment integrated building group risk management process inclusive designed collaboratively colleagues across multiple functions gathered insights broad range internal external stakeholders economy identify important pressing issues roche address next three five years identified material topics clustered eight main categories stood highly relevant us key stakeholders properly address topics aligned current goals measuring performance defined set indicators impact impact performance material topics supporting un sdgs society million patients treated access healthcare contribute roche medicines digitalisation better tomorrow billion tests conducted science innovation roche diagnostics products product quality safety new molecular entities ethics compliance clinical development employee engagement women executive positions women management employee engagement score environment decrease environmental energy efficiency minimise impact per employee since impact nature electricity coming sustainable sources decrease greenhouse gas emissions since economy sales invested rd longterm mindset invest medical advances employees create jobs ensure livelihoods clustered material topics details see rochecommateriality strategy focus finding new medicines diagnostics establishing databased insights evolve practice medicine help patients live longer better lives business environment undergoing tremendous seamless patient journey continue change facing new challenges due concentrate energies prescription medicines complexity care increasing pressure vitro diagnostics increasingly data healthcare budgets time see new insights rather diversify sectors opportunities arising major advances life like generics biosimilars overthecounter sciences digitalisation healthcare medicines turbulent times guided delivery create value common purpose patients stakeholders partner choice bringing need next company bringing significant medical benefit patients doctors novel diagnostics treatments patients payers offering great place work years patients remain core employees delivering sustainable positive reason come contribution society earning competitive work every day returns investors focus vision fitting treatments ultimately delivering commitments takes patients providing right therapy right people integrity courage passion patient ensure best response right making difference patients people time right value approach combines proud say roche rich expertise pharmaceuticals diagnostics expanded data science capabilities drive leadership inspires outcomes matter effective efficient research enable embracing diversity inclusion different better therapeutic decisions patients backgrounds perspectives experiences across entire organisation foster innovative solutions pursuit excellence science rests four benefit patients ways working key elements exceptionally broad deep enable agile networked responses ever understanding disease biology seamless increasing pace change balancing needs integration capabilities pharmaceuticals stability speed flexibility diagnostics diversity approaches maximise innovation longterm orientation setup designed innovation autonomous research development centres working partnership third parties alliances external partners offer integrated solutions improved medical foster diversity scientific approaches health economic benefits work agility global geographical scale reach many different stakeholders healthcare enables us attract talent leading global ecosystem broaden access offerings science clusters quickly bring solutions people need ultimately provide people need themour strategy roche focus leadership fitting treatments patients inspiring outcomes matter distinctiveness ways working excellence science agile networked delivery setup value stakeholders built innovationdiagnostics roche diagnosticsdiagnostics roche diagnostic solutions backbone treatment decisions whether cancer infectious diseases serious health threats quest better solutions healthcares greatest challenges depends diagnostics covid pandemic profoundly raised first quarter also introduced awareness role diagnostics play disease sarscov antigen self test nasal prevention management although covid selfadministered testing home test continues dominate healthcare landscape enables patients gather sample pandemic remains global threat front area nose rather nasopharynx countries made varying degrees progress identify infectious sarscov towards containing virus end minutes initially granted special approval million confirmed cases several european countries test received covid five million deaths ce mark june expanding availability countries accepting ce mark spread virus placed enormous strain health systems heightened need supplemented covid portfolio millions tests roche proud june launch sarscov assay industryleading portfolio covid solutions cobas liat system making first minute remain committed developing pointofcare poc pcr test receive emergency bringing market additional tests solutions use authorization us asymptomatic strengthen global fight disease screening test detects currently known sarscov variants brings fast pcr testing march launched cobas nearpatient settings like clinicians offices sarscov set variant test runs emergency rooms urgent care clinics cobas systems developed detect differentiate sarscov mutations known december received fda emergency use variants researchuseonly test help authorization covid athome test scientists track mutation prevalence assess uses simple anterior nasal swab sample spread circulating variants monitor convenient selfcollection selftesting potential impact treatments vaccines public individuals aged years older adult health measures test preoptimised assay children aged years old produce design readytouse test cassettes predefined accurate reliable quick results software parameters reduce testing minutes sarscov known variants complexity shorten turnaround time concern including omicron navify pass enables individuals receive health credentials easily seamlessly mobile devices month added three additional researchuseonly ruo test kits detection mutations present novel b omicron sarscov variant virsnip sars spike insepe ruo virsnip sarscov spike sl sp ruo virsnip sars spike ea ruo kits developed tib molbiol newly acquired subsidiary virsnip variant kits allow differentiation range unique mutations present within omicron variant compared sarscov variants use lightcycler cobas z analysers using technology called quantitative polymerase chain reaction qpcr help researchers improved variant detection viral research among first address range unique mutations omicron variant besides novel assays also launched navify pass digital solution allows people years milestones receive covidrelated health data mobile app available various countries revolutionising diagnostics including united kingdom netherlands polymerase chain reaction pcr trusted way create unlimited solution used facilitate access copies dna one original strand copied dna events travel enable return normality used reliably wide variety tests diagnose monitor diseases basic molecular biology research pointofcare testing plays essential increasingly important role healthcare kary mullis scientist cetus corporation conceived pcr delivers high medical value solutions method copy dna synthesise large amounts specific target diagnostic information patients healthcare dna next two years team cetus scientists recognised professionals wherever whenever needed potential impact pcr could molecular biology researched roche pointofcare strategy focuses refined made theoretical process reality infectious diseases like covid influenza ab sepsis tests several diseases roche bought rights pcr cetus invested currently development refining science use molecular diagnostics detect diseases roche molecular diagnostics defined refined pcr remained clear leader trailblazer technologydiagnostics roche diagnostics beyond covid unfortunately pandemic many people oesophageal cancer mutation p present serious diseases face delays treatment half solid tumour cancers common disease monitoring achieve best genetic change identified far human cancers possible results patients depend heavily test especially impactful oesophageal early diagnosis rapid access therapy cancer sixth common cause cancer meet covid testing needs death worldwide particularly difficult significantly increased installations treat often signs symptoms highthroughput systems cobas early stages installed result every hours laboratories around world also support phc approach towards perform three million tests could cancer care received fda approval october pandemic health systems use ventana pdl sp assay used additional capacities screening diagnosis companion diagnostic identify patients treatment monitoring areas cancer nonsmall cell lung cancer eligible treatment cardiovascular disease womens health tecentriq immunotherapy approval based results phase iii spite pressures meeting ongoing impower study expands industryleading demand covid tests launched several portfolio companion diagnostics tests solutions health conditions many conditions also launched elecsys growth differentiation tremendous stress strain patient also factor gdf immunoassay detects loved ones healthcare system specific form weight loss known cachexia patients solid tumours test oncology added important new tests received fda breakthrough device designation aid fight cancer march helps determine eligibility treatment targets expanded label ventana alk df highly prevalent complication cancer assay identify alkpositive lung cancer patients eligible targeted treatment ventana mmr rxdx panel launched april lorbrena lorlatinib pfizer assay first fdaapproved companion diagnostic immunohistochemistry test approved fda identifying patients advanced recurring companion diagnostic lorbrena test endometrial cancer best suited previously approved companion treatment gsks immunotherapy drug jemperli diagnostic three targeted treatments dostarlimabgxly endometrial cancer including xalkori crizotinib pfizer zykadia ceritinib common gynaecologic cancer us novartis roches alecensa alectinib women globally die endometrial cancer label expansion advances roches commitment year currently limited treatment options personalised healthcare phc provides lung exist women whose disease progresses cancer patients access treatment firstline therapy first companion options better chance progressionfree diagnostic identify endometrial cancer patients survival compared standard care eligible antipd immunotherapy test also fda approved august help determine month later launched elecsys antip based cancer biomarkers patients immunoassay help diagnose bowel breast solid tumours may benefit jemperli systems tests software solutions help laboratories improve efficiency quality controls information sharing support physicians patients treatment decisions women increased risk highgrade cervical precancer require immediate diagnostic procedures women may need repeat testing routine screening improving cvd management cardiovascular disease cvd remains leading cause death globally claiming lives nearly million people year covid pandemic made management disease even challenging especially many patients unaware disease reluctant seek care even experiencing classic symptoms like chest pain biomarkers play critical role improving diagnosis management heart attacks heart failure april announced additional testing capabilities two key biomarkers highsensitive cardiac troponin ctnths nterminal probrain natriuretic peptide ntprobnp heart failure affects million people october announced impact improving worldwide places great stress patients primary screening colposcopy triage clinical caregivers healthcare systems despite trial data showing clear benefit using treatment hospitalisation outlook poor cintec plus cytology test women one new elecsys ntprobnp test extensions higher risk developing cervical cancer identify patients type diabetes women diagnosed cervical cancer greater risk developing heart failure another year approximately die helps identify patients risk developing atrial preventable cancer caused infection fibrillation abnormal heart rhythm highrisk types human papillomavirus hpv lead stroke brain damage death new results trial women extensions elecsys ctnths testing help predict aged years published heart attack risk mortality noncardiac international journal cancer surgery patients assess longterm cardiovascular event risk asymptomatic patients study women positive high risk hpv received followup triage test help infectious disease threats beyond covid determine cervical cells transforming although covid retains worlds attention cervical precancer biomarkerbased range infectious diseases affect millions cintec plus cytology test showed significantly people rank among top three causes higher sensitivity detecting cervical precancers death worldwide continue develop tests compared pap cytology roche test aids solutions infectious diseases beyond clinicians confidently determining covid fact sheet cardiovascular diseases world health organizationdiagnostics roche march launched elecsys epsteinbarr identify multiple pathogens overlapping virus ebv immunoassay panel improve ebv symptoms test panels run staging countries accepting ce mark cobas omni utility channel highvolume infecting worlds population cobas systems three new adulthood ebv normally remains dormant molecular diagnostic panels use single patient become threatening sample test influenza influenza weakened immune systems transplant b well respiratory syncytial virus rsv patients panel includes three immunoassays adenovirus adv human metapneumovirus detect specific ebv antibodies elecsys igm hmpv enterovirusrhinovirus evrv elecsys ebv vca igg elecsys ebna igg parainfluenza tests panel helps clinicians make faster decisions run together alone compared treatment transplant patients also conventional diagnostic methods flexible used rule acute infections syndromic panels reduce unnecessary testing undetected hiv provide important insights clinicians quickly moreover tests also newly approved claim extension combined covid testing elecsys brahms procalcitonin pct immunoassay cobas systems monitor patients antibiotic therapy around million patients year aids patients respiratory infections often identifying resistance enables targeted signs symptoms specific enough antibiotic use also detects severe bacterial discern root cause illness infections many million patients year latest set syndromic respiratory solutions earlier therapeutic intervention allows clinicians choose appropriate tests based healthcare setting seasonal completion genmark diagnostics outbreaks patient needs testing acquisition strengthened broadened medically relevant necessary enable infectious diseases portfolio taken targeted therapy avoid misuse antibiotics major step syndromic panel testing also reduce unnecessary intervention known multiplex testing detecting common pathogens cause disease together acquisition tib molbiol group single rapid test single patient sample december able expand clinicians prescribe right therapeutic portfolio ceivd assays within hours rather days compared research use assays lightcycler conventional testing algorithms roche pcr systems magna pure sample preparation genmark benefit patients laboratories systems successfully partnered healthcare providers combined tib molbiol years expertise portfolio collaboration instrumental creating first sarscov detection test january acute respiratory infections including serious mere days novel virus first complications infections sarscov sequenced among worlds leading causes death disability september launched three respiratory test panels ce markets help transforming healthcare digitalisation advanced technology billion tests conducted pathology algorithms upath ki upath roche products includes er sp upath pr e image analysis one billion tests diagnose sarscov infections also breast cancer three important measure related antibodies addition biomarkers complete digital pathology includes millions tests health conditions breast panel image analysis algorithms time thousands data points individual patients create throughout journeys earlier detection liver cancer specifically help identify changes health also hepatocellular carcinoma hcc ce mark enable tracking similar patient cohorts across granted november elecsys gaad institutions geographies eventually algorithmic score combines gender age allow comparison outcomes well roches elecsys afp elecsys pivkaii assays predictive measures artificial intelligence liver cancer one cancers ai machine learning rise responsible deaths year however detected managed early goal improving patient care patient fiveyear survival rates increase expanding access innovative image analysis algorithmic score helps aid diagnosis launched digital pathology open environment patients chronic liver disease open environment roche building hepatitis cirrhosis followedup ct open application programming interface api mri scanning provides clinicians framework enable thirdparty companies accurate information support treatment deploy algorithms within navify digital decisions could help increase access liver pathology cloud version roche upath cancer testing enterprise software addition digital pathology open environment announced digitalisation pointofcare setting october collaborations pathai ibex cobas pulse system represents major advance medical analytics aibased digital pathology revolutionary new glucose management applications solution first professional blood glucose meter androidbased operating system growing involvement ai underscores loaded industryleading medical apps belief holds significant promise advancing perform essential functions nurses doctors pathology imaging benefit cancer lab managers cobas pulse launched patients precise diagnosis november believe system serve turn help clinicians identify targeted treatments gateway future digital health services could lead better results medical practice breast cancer announced january improved lab management improved ceivd launch automated digital pathology patient outcomes algorithms upath b image analysis innovative tests digital insights enhanced upath dual ish image analysis laboratory management solutions transforming help determine best treatment strategy healthcare improving outcomes new patient december launched three digital era come great opportunities benefit new researchuseonly ruo automated digital patients laboratories around world bydiagnostics roche digitalisation healthcare continually improving ability collect curate make sense vast quantities diverse patient data identifying developing innovative predictive diagnostics testing enables early detection treatment significantly improve outcomes addition ai help increase number cases reviewed pathologists reducing human error improving accuracy enabling personalised treatment plans third quarter launched updated expanded lab analytical applications customers including viewics labops molecular newly expanded offering provides insights across entire menu roche cobas systems using data directly uploaded analytics roche viewics labops core approved launch several regions around world enhancing digital diagnostics portfolio application provides laboratory hospital personnel easier way track review identify operational trends challenges visibility guides decisionmaking process towards optimising operations customer delivery overall lab performance targeted efficient manner labops core providing set turnkey analytics thereby enabling data driven decisions improve operational effectiveness clinical laboratories also launched new diagnostic platforms cobas pure cobas pro high throughput cobas new systems enhance offering enabling comparable results labs different sizes first two serum work area space core laboratories latter molecular labs roche goal provide patientcentric continuity care every stage patient journey prevention diagnosis treatment monitoring aftercare diabetes care diabetes management complex personal handset algorithm analyses data real time achieving therapy goals ongoing challenge decides whether stop insulin delivery adjust believe personalised tailored basal rates even deliver automatic correction therapy better outcomes bolus needed continue implement solutions leverage integrated personalised diabetes management also april mysugr acquired roche approach announced integration novo nordisk novopen novopen echo plus mysugr april diabetes care began offering app logbook ios integration follows accuchek insight insulin pump paired collaboration agreement signed roche diabeloops hybrid closedloop system within novo nordisk users record scope previously announced partnership insulin data mysugr app track combine people living diabetes germany italy spain blood glucose values activities meals switzerland netherlands able relevant diabetes data solution use accuchek insight insulin pump part currently available sweden denmark diabeloops dblg system features well pilot projects selected healthcare selflearning algorithm hosted dedicated institutions germany austria mysugr app integral part diabetes care open ecosystem offers features like mysugr app fully integrates rochediabetes structured documentation data accurate insulin care platform dose calculations reminders coaching help people better manage daily diabetes routine fully integrates rochediabetes care platform enables healthcare professionals comprehensive overview relevant patient data also features remote patient monitoring even important people diabetes spending significantly less time physicians due covid pandemic may signed collaboration agreement eli lilly company integrate data companys connected insulin pen solution roches open ecosystem mysugr app paired mysugr app tempo smart button automatically transfer data via bluetooth technology mysugr logbook thus roches open diabetes management ecosystemdiagnostics roche test results produced systems billion cobas systems installed active inlicensing agreements active outlicensing agreements diagnostics facts covid tests enabled per month million new assays panels algorithms oncology diabetes care diagnostics tests solutions currently covid portfolio new launches digital decision support new assays claim extensions laboratory insight solutions solutions infectious cardiovascular diseases diagnostics roche lung cancer patient going cure amanda nerstad mom alkpositive lung cancer shares story importance biomarker testing raising money cure jogging hills tennessee home lemonade cure united states amanda found gasping neighbourhood lemonade stands inspired breath friend diagnosed daughters incredible support pneumonia young mom wondered family friends nerstad family raised might usd lung cancer research since among projects helped fund trip doctor day launched alk vaccine study hope turn harrowing journey within days amanda non terminal disease chronic illness going smoker diligent health fitness cure amanda says alkpositive diagnosed stage iv lung cancer told might lung cancer given us platform raise money little two weeks live amandas first research cure thought daughters isabella greta put notes lunchboxes every morning also driven change negative bias great day mommy loves thought whos toward lung cancer patients everyone wants going write notes devastating know get lung cancer one ever asks someone breast cancer got search clues driving amandas one first questions everyone asks cancer oncologist ordered tests whether smoked important know nervously waiting results biomarker testing anyone lungs get lung cancer nerstads found something powerful hope amanda also dedicated inspiring researchers welcome news industry leaders including roche amanda tested positive change celebrate year anniversary drive anaplastic lymphoma kinase alk gene innovation hope next years roche found four percent nonsmall cell lung help move research forward annual cancer cases candidate targeted cancer testing available everyone treatment specifically people test positive hopefully catch cancer early says mutation first months treatment left amanda exhausted ill doctor surrounded positivity suggested new alktargeted therapy today amanda finds joy making difference celebrates complete metabolic response cancer warriors sweet moments wrapped evidence disease side effects love family determined every aspect life time important amanda mission spread word us live enjoy moments importance biomarker testing sharing lovely laughter around dinner experiences survivors many young moms table snuggles couch favourite like fundraises alk positive movie surround positivity nonprofit organisation raised embrace every day together amanda says usd million alkpositive lung cancer research going curepharmaceuticals roche pharmaceuticalspharmaceuticals roche driving patient benefit burden poor health increasing growing populations higher life expectancies increase chronic diseases continued discrepancies access healthcare means demand healthcare continues grow systems struggling keep industry society need pharmaceuticals investigational rethink innovate provide antiviral medicine covid care sustainable way milestones covid portfolio roche long history developing ronapreve delivering breakthrough medicines made march new phase iii data showed meaningful difference lives millions ronapreve reduced hospitalisation death people worldwide todays world nonhospitalised patients covid must making april phase iii prevention trial showed fundamental changes way operate subcutaneous administration ronapreve work stakeholders partners reduced risk symptomatic covid leverage developments science infections technology deliver matters june university oxford announced patient benefit far less cost society preliminary phase iii results uk recovery study patients hospitalised time bold new approaches needed covid results showed ronapreve going part bring reduced risk death solutions mounted natural antibody response seronegative efforts pandemic joining july japan first country approve forces patients society ronapreve treatment mild moderate covid spurred us rethink partner covid followed eu approval treatment develop diagnostics treatment options prevention november work speeds never could september phase iiiii trial data showed imagined goal delivering innovation ronapreve significantly reduced viral load within patients seven days treatment patients hospitalised covid building partnering efforts september recommended use continued work gilead sciences ronapreve nonsevere covid patients combination study evaluating two medicines highest risk severe disease roches actemraroactemra gileads veklury patients severe critical infection hospitalised patients severe covid seronegative status associated pneumonia also furthered october ronapreve together actemra work regeneron antibody cocktail roactemra included eu casirivimab imdevimab ronapreve please see commissions portfolio ten promising story worked atea covid treatments throughout pandemic production logistics teams demonstrated deep commitment serving patients worldwide july issued new treatment guidelines covid recommend interleukin il receptor blockers actemra roactemra patients hospitalised severe critical covid december european commission extended marketing authorisation actemraroactemra include treatment covid adults receiving systemic corticosteroids require supplemental oxygen mechanical ventilation decision came hours recommendation european medicines agencys committee medicinal products human use reflecting urgent need medicines tackle covid pandemic june atea pharmaceuticals announced interim results phase ii ata trial hospitalised patients moderate covid high risk poor outcomes november new sarscov variant interim results indicated rapid sustained omicron b classified variant antiviral activity sarscov patients concern analyses shown hospitalised setting ronapreve retain neutralising october atea pharmaceuticals announced activity omicron variant ronapreve results phase ii moonsong study retains activity main nonhospitalised patients variants concern including delta activity mild moderate covid study ronapreve potential future variants meet primary endpoint showing continually assessed significant reduction viral load baseline compared placebo overall study actemraroactemra population june roches actemraroactemra received november roche atea pharmaceuticals us fda emergency use authorization communicated roche decided end treatment covid hospitalised adults partnership atea programme children focus efforts covid activitiespharmaceuticals roche pharmaceuticals clinical pipeline phase phase ii phase iii registration oncology inflammationimmunology neuroscience infectious diseases ophthalmology metabolics others pipeline new molecular entities covers broad range diseases highly innovative technologies applied create produce active molecules advancing clinical trials clinical trials essential medical progress study comprises mostly european populations data trials helps scientists clinicians little representation communities understand investigational medicines affect noneuropean descent difficult different groups people specific genetic understand diverse genetic variants play markers disease supports development role progression disease targeted personalised treatments closing gaps real world demographics accurately makeup clinical matter trials represents realworld demographics past several years focusing robust data ultimately efforts closing gaps clinical trials effective medicines might patients ensuring accurate representation patient need populations around world results research collaboration genentech deeply committed addressing barriers stanford university known trial pathfinder clinical trial participation widening access published scientific journal nature expanded innovative diagnostic study highlights realworld data therapeutic solutions diversifying genetic artificial intelligence ai could used help data advancing inclusive research globally address underrepresentation clinical research nonsmall cell lung cancer nsclc missed opportunities across industry around global clinical recent studies show majority nsclc trial participants european ancestry patients meet criteria participate represents global population clinical trials due restrictive inclusion criteria additionally genomic data trials fail complete recruitment available european ancestry leaving within targeted time trial pathfinder showed significant amount data undiscovered using datadriven approach eliminate restrictive eligibility criteria could increase gaps mean trial results always total number eligible patients applicable patient populations miss twice many including enormous amount valuable data women africanamericans well studies consider instance even broader range ages without compromising though black women mortality rate study outcome breast cancer approximately greater caucasian women represent pandemic disproportionately women trials studying disease devastatingly impacted people colour initiated clinical trial one investigational determining treatments work best medicines covid pneumonia global patients requires great deal clinical trial sites enrolled highrisk minority genomic data currently data available public populations included order enhance total gwas participants diversity genomewide association studies gwas diversity monitor cancer facts figures african americans american cancer society enrollment racialethnic minority patients ovarian breast cancer trials fda analysis journal clinical oncology evaluating eligibility criteria oncology trials using realworld data ai naturepharmaceuticals roche deeply committed addressing barriers clinical trial participation patient populations around world understanding clinical profile actemra roactemra patients allow access underserved minority populations commonly represented clinical trials approximately participants represented communities colour including hispaniclatinx native american black populations advancing participation representative patient populations genentech initiated advancing inclusive research site alliance coalition clinical research centres building sustainable ecosystem order facilitate inclusion historically underrepresented people clinical research together aim advance participation diverse patient populations oncology trials test recruitment retention approaches establish best practices leveraged across industry disease areas help achieve health equity people four inaugural partners successfully including diverse populations clinical trial efforts mays cancer center san antonio texas oneal comprehensive cancer center birmingham alabama west cancer center memphis tennessee city hope comprehensive cancer center los angeles california recognise bringing real change requires partnership industrywide investments partnering across healthcare ecosystem collectively combine scientific advances new technologies realworld data create new standards inclusive clinical research shaping next years science pace new drugs discovered adaptive biotechnologies since developed rapidly increasing never develop type personalised cellular therapy exciting time transform deliver care patients committed genentech expanded commitment exploring uncharted areas access previously cell therapies new collaboration signed unreachable targets along partners adaptimmune therapeutics september envision future latest greatest develop tcell therapies various solid science technology drive innovation tumours another collaboration entered unlock future healthcare december lineage cell therapeutics develop commercialise retinal gene therapy pigment epithelium rpe cell therapy specific gene therapies potential address ocular disorders also ongoing partnerships previously untreated diseases replace existing companies like biontech mrnabased therapies potential onetime treatments nykode therapeutics dnabased develop quest follow science strengthen therapies aimed training immune system presence promising emerging modality two recognise patients neoantigens similar years ago roche acquired spark therapeutics vaccines used successfully provide leading gene therapy company today sparks immunity sarscov infections expertise combined roches broad rd skills commercial capability global reach along advances data technology patients partners puts us unique one million medical papers position unlock full potential gene therapy published year clinician enough time immerse latest increasingly work area august complex research decide right therapy entered research collaboration license individual patient advances data agreement shape tx developed technology analytics enable novel form gene therapy edits genetic clinicians make better treatment decisions messages level mrna without changes faster allow us solve problems dna excited work together bridge gaps across healthcare ecosystem develop therapies certain targets areas drug discovery development approval alzheimers disease parkinsons disease diagnosis disease monitoring access care rare diseases envision future data technologies analytics routinely accelerate drug discovery cell therapy development enable better patient care cell therapy another promising emerging employees across roche group worked modality active cell therapy together partners bring future studies ongoing worldwide closer exemplified following initiatives product candidates development cancer immunotherapy cell therapy showing discovering selecting best drug potential effective approach harness candidates persons immune system fight cancer follow drug discovery many benefits hypothesis genentech collaborating utilising artificial intelligence ai roches clinical pipeline cancer cell therapies naturepharmaceuticals roche envision future latest greatest science technology drive innovation unlock future healthcare pharmaceutical research early development pred organisation developed machine learning operationalisation platform ml ops enables embedding machinelearning models daily routines nondata scientists bringing ai fingertips teams using platform predict different properties small molecules enabling faster selection good drug candidates following aspiration roche genentech teamed companies like reverie labs genesis therapeutics generate new compound designs predict properties thereby advancing preclinical development small molecule medicines addition genentech recently acquired prescient design support application ml optimisation de novo design therapeutic antibodies power prediction clinical trials ai computational approaches years milestones used analyse large amounts data gathered clinical trials leading better understanding patient outcomes example taking risks patients part imvigor study urothelial years origin multiple sclerosis ms autoimmune disease cancer scientists looked various biomarkers central nervous system mystery tcells identified found directly blood assess primary culprit treatments ms focused patients specific biomarkers need additional therapy retrospective analysis dr stephen hauser current director weill institute data showed patients without detectable neurosciences university california ucsf researchers amount circulating tumour dna ctdna hypothesised bcells another component immune system better chance becoming diseasefree also played critical role causing inflammation leading ms better overall survival rates results led research met scepticism scientific community directly initiation another phase iii study academic funding granted adjuvant bladder cancer prospective selection ctdnapositive patients genentech willing take risk agreed go forward outcome potential change clinical earlyphase clinical trial estimated chance practice improving probability success success three decades research able refine new clinical trials allowing smaller shorter molecule breakthrough opened new treatment possibilities trials focused patients need additional revolutionised understanding ms treatments increasing data insights capabilities allow us focus vision providing right therapy right patient right time gathering making sense large amounts data advances technology also highlight fact incredible amount data collected across various stakeholders countries systems across roche group focused better ways gather structure make sense data direct data connection ddc initiative example reinventing flow data clinical trial sites back roche automating endto end stream patient trial data electronic health record ehr systems sponsor electronic data capture edc systems ddc initiative eliminates need duplicative manual data entry allows realtime errorfree access clinical trial data userfriendly software solution tested sites around world received positive feedback site coordinators study team members able make realtime decisions patients another example work area new partnership alan turing institute uks national institute data science ai teams develop apply advanced analytics methodologies generate insights multiple types healthcare data improve understanding impact patients individual disease characteristics response different therapies ultimate goal enhancing clinical care people around worldpharmaceuticals roche products outlicensing acquisitions agreements divestments product technology discovery licence agreements agreements derived number new existing alliances partnerships phc agreements research discovery collaborations japan chugai us polivy alecensa mabtherarituxan mabtherarituxan evrysdi tecentriq ronapreve indications actemraroactemra xolair major approvals susvimo port delivery system ranibizumab china europe avastin indications gavreto gazyvagazyvaro tecentriq hemlibra venclextavenclyxto azacitidine kadcyla actemraroactemra covid tecentriq enspryng tecentriq pemetrexed evrysdi enspryng ronapreve indications evrysdi xofluza indications xofluza indications oncology inflammationimmunology neuroscience infectious diseases ophthalmology pandemic drastically altered scale urgency needed develop distribute covid treatments diagnostic testspharmaceuticals roche opening new possibilities fight covid face covid pandemic collaboration jointly develop increase healthcare community looked ways global distribution regenerons covid address ongoing situation around world antibody combination called parties acknowledging great responsibility feel embrace new mindset challenge ways society coupled capabilities things expertise asked help results word amazing within days knowing clinical worked tirelessly develop testing studies would successful teams completed solutions investigate drug substance technology transfer medicines covid understood would process usually takes nine months take extraordinary mobilisation collaboration took six months day roche across entire healthcare ecosystem defeat first received manufacturing details strong partnerships always delivered first products countries around cornerstone work roche approximately world thanks shared vision momentum half medicines result successful partnership trials antibody collaborations companies institutions combination moved phase phase iii around world knew could contribute months data trials early scientific knowledge clinical research promising particularly prophylaxis expertise infectious diseases antibody treatment highrisk hospitalised patients based therapeutics well skilled workforce entered bilateral agreements specialised manufacturing capabilities increasing number countries antibody pandemic drastically altered scale combination authorised emergency use urgency needed develop distribute covid received first official approvals japan treatments diagnostic tests leading us july followed eu november collaborate new ways work speeds never could imagined time willingness take risks well go alone meant reaching tireless effort unwavering commitment parties including competitors see involved none would could together possible despite feelings uncertainty fear difficult operating conditions due global entered partnership us lockdowns teams embraced challenge biotechnology company regeneron embarked open mind goal sight develop journey full new experiences challenges manufacture potentially lifesaving medicines one jawdropping milestone another impact would felt around worldpharmaceuticals roche elusive diagnosis lifetime perseverance hope age liz adams diagnosed spinal muscular atrophy sma rare neuromuscular disorder results loss motor neurons progressive muscle degeneration liz thanks positive mindset feels content ever liz almost two years old started language liz explains point liz walk throughout childhood experienced walking cane still enjoyed travelling physical weakness got older wondered working developed adventurous spirit frequently fell hands shook returning home korea became could run fast friends interpreter deaf working public schools time symptoms worsened fayetteville north carolina asked parents take doctor started long process going doctor liz married mum four kids doctor nobody knew wrong sam joyful rebekah david says liz uses wheelchair enjoys exercising spending time outdoors usually swim two sma well known time three times week regularly use rowing another four years passed finally machine invigorates lot says liz diagnosed point parents told also really excited participating nothing could done upcoming km race first one people type sma lose ability walk wheelchair overarching attitude point lives require mobility perseverance really stuck liz entire support hard hear dad life love set goals setting high determined make best goals trying reach even adds years following diagnosis liz modified version original goal motivates parents figured exercises read lot explains educated sma built support system friends family liz excited recent scientific developments sma encouraged growth liz went college studied awareness disease last decade american sign language pottery im starting personal experience late handson person challenge turn therapy available away graduated lived south korea treatment options possibilities amazing months taught english foreign concludes liz smilepersonalised healthcare roche personalised healthcarepersonalised healthcare roche future healthcare lies tailormade solutions improving lives always heart year history commitment innovative science led lifechanging discoveries patients recently focused much attention early comprehensive diagnosis developing new technologies enable advanced diagnostics measurement tools us personalise healthcare allow us predict likely become ill diagnose illness earlier understand unique efforts develop individualised approach characteristics patients condition care date back early roche response treatment digital solutions help genentech pioneered commonly close gaps along care continuum areas known personalised healthcare phc back prevention disease monitoring even bringing targeted treatments patients effective incorporate thirdparty data goal today reality combining unique expertise pharmaceuticals diagnostics one major challenges diagnosis datadriven insights continue move preparation specimen dna especially forward remain united goal complex prepare sequencing prone integrating elements care order create human error launched avenio edge truly personalised experience patients system simplify automate nextgeneration sequencing sample preparation reduce human error introducing care continuum advance precision medicine future part goal expand personalised healthcare shifted treating diseases also recently introduced open digital focusing holistic peoplecentric approach pathology environment enables pathologists spans entire care continuum change exchange data securely also provides entails fundamental shift way understand access roche image analysis tools well deliver healthcare thirdparty technology among first un sdgs collaborations within framework joint ensure care continuum approach development agreement made october successful tapping deep internal ibex medical analytics global leader resources expertise time artificial intelligence aibased cancer diagnostics capitalising strengths independent agreement jointly develop material topics affiliates flatiron health foundation embedded image analysis workflow pathologists patient centricity medicine also partnering external seamlessly access ibexs ai algorithms insights rd efficiency stakeholders across healthcare ecosystem decision support tools using navify digital personalised healthcare help deliver right treatment right patient pathology cloud version upath realworld data right time enterprise software preparedness ageing society powered data analytics novel sensitive quantitative measures highquality data rigorous analytics make patients empowered monitor engine drives phc today healthcare variety diseases ability establish produces vast amount untapped data deep understanding patients metrics holds potential unlock valuable insights daily basis time lead broad range roche diagnostic solutions tailored effective care alone produces billions data points year every single one holds highquality data indicates continuously reporting information could spark small advancement symptoms disease effects cancer therapy personalised healthcare brought together facilitate shared approach disease contribute longitudinal data management patients care teams massive scale enabling comprehensive also increase survival improve quality view patients life reducing symptom burden emergency room visits hospitalisations maximising true potential data dataenabled technology hinges patient trust continued reliance clinic visits build maintain trust maintain primary way assess monitor patients remains highest standards data privacy deidentification fundamental limitation healthcare personal security additionally increasing technologies including wearables medical expertise data handling added various devices allow patients play active digital health offerings portfolio role tracking managing health early roche announced launch multiple sclerosis ms insidious navify pass important expansion unpredictable disease hard track broad response covid pandemic measure launch smartphone application cloudbased solution consists mobile app floodlight us germany finland helps individuals healthcare professionals make precision monitoring reality people living well backend tool testing sites navify ms simple tasks drawing pass also enables unconventional pointofcare shape app enables physicians patients sites fully digitise workflows shed light impact disease first test performed government reporting individual patient furthermore data point application enables individuals store contributes unique data set designed move results selfadministered tests well ms research forward administered medical facility professional site collaboration moorfields eye hospital london roche piloted home vision monitor remote patient monitoring management interactive smartphone tabletbased app roche forefront diagnostics empowers patients test monitor changes disease monitoring decades vision app designed people early among first develop diseases affect macula athome automated selfmonitoring blood agerelated macular degeneration diabetes glucose meter people diabetes today moorfields patients used ushering new era physicians use app claiming offers peace ofpersonalised healthcare roche navify pass cloudbased solution consisting mobile application individuals healthcare professionals well backend tool testing sites mind knowledge documenting changes vision checkups partnerships collaborations unlocking full potential phc integrating advances medical science data technology care continuum demands holistic thinking collaboration among stakeholders across healthcare ecosystem part commitment accelerating effort partnering organisations create new approaches solutions roche joined autism sharing initiative new project build first global network sharing genomics clinical data accelerate breakthrough discoveries precision healthcare autism using new technology initiative allows search analysis performed across multiple individual data sets information remains protected local environments years milestones june genentech presented results collaborative efforts pathai improved clinical assessments nonsmall cell lung turning point cancer treatment cancer partnership pathai accelerates last century cancer categorised location understanding patient response lung body result treatment results varied significantly cancer treatments september fda approved roche genentechs breast develop innovative products cancer therapy herceptin many regards approval marked digital solutions also work stakeholders turning point cancer treatment jointly address obstacles make phc solutions accessible patients around world march monoclonal antibody specifically designed treat patients roche canada signed memorandum metastatic breast cancer whose tumours overexpress protein collaboration british columbia cancer herceptin first targeted treatment solid tumour agency canadian personalized healthcare also first drug paired companion diagnostic innovation network known predict precision identifying patients improved riskbenefit profile patients oncology evidence development cancer gained critical time would otherwise spent search treatment proven successful initiative viable treatment generate assess realworld evidence rwe may used shape new sustainable reimbursement pathways personalised cancer treatments critical step sustainable healthcare transformation lead better impact pandemic time elapsed care lower cost people society diagnosis initiation systemic please see story treatment cancer patients american society clinical oncology asco accepted foundation medicine flatiron health study well extensive additional work help independent affiliates roche group oncology practices assess address frontline pioneers field healthcare data impacts analytics together built clinico genomic database links two largest part leadership rwe regulatory sources clinical genomic realworld data policy frameworks flatiron helped establish rwd integrated data set serves rwe alliance industry organisation valuable resource accelerating precision whose goal collectively identify develop oncology linked patient records advocate technical regulatory policy available research end solutions advance use rwe reflecting growth year regulatory decisions flatiron health furthermore flatiron taken major steps flatiron health continuously expanded ensure interests priorities patients us network community oncology practices considered research strategy academic medical centres community steps include launch formal mechanisms oncology partners alone saw daily average patient engagement us uk patients addition oncologists already using flatiron assist decision foundation medicine support tool quickly select evidencebased together roche foundation medicine offer treatment options patients also portfolio comprehensive genomic profiling flatiron began expand network beyond cgp tests solid haematological tumours us building new partnerships derive rwd tests enable easier faster better hospitals health networks europe asia clinical decisions partners two companies leading implementation uptake despite impact covid traditional cgp around world goal developing clinical trials prospective clinicogenomic personalised treatment strategies oncology pcg study partnership among flatiron well smarter efficient diagnostic foundation medicine genentech us solutions foundation medicine services community academic oncology practices available countries worldwide enrolled patients metastatic lung cancer across sites study august japans health authorities designed seamlessly integrate clinical approved use reimbursement research clinical care offer participants foundationone liquid cdx bloodbased cgp serial genomic testing may test analyses cancerrelated otherwise access genes solid tumours provides better understanding driving patients flatiron published several important cancer grow gives insight personalised studies including one highlighted treatment options patientpersonalised healthcare roche foundation medicine tests enable easier faster better clinical decisionmaking comprehensive genomic profiling cgp additionally fda approved companion diagnostic claims foundationone cdx foundationone liquid cdx bile duct cancer nonsmall cell lung cancer nsclc foundation medicine companion diagnostic approvals across two fdaapproved tests partnership natera foundation medicine launched foundationone tracker research use tracker personalised circulating tumour dna ctdna monitoring assay combines foundation medicines tissuebased cgp platform nateras expertise ctdna monitoring addition roche launched new genomic profiling kit helps cancer researchers sequence tumours without send tissue samples centralised laboratories avenio cgp kit powered foundationone research useonly allows healthcare professionals apply highquality cgp local labs giving patients opportunity participate trial leverages cgp foundation medicine also made several updates across portfolio help expand access precision oncology integration flatiron healths oncoemr platform improves efficiency clinical decisionmaking enabling electronic ordering order tracking receipt foundation medicines cgp test results forthcoming integration epics electronic medical record system also streamline access genomic insights precision cancer care genomic data also helps us better understand diagnose treat patients rare cancers personalised level ongoing cupisco study randomised trial using cgp assign patients cancer unknown primary cup targeted immunotherapy treatment aims shed light disease high medical need addition using foundationcore one largest cgp databases oncology allows genomic data helps us better understand diagnose treat patients rare cancers personalised level researchers learn characteristics ntrk fusionpositive cancers rare molecular subgroup cancer making phc accessible everyone two decades passed since roche took first steps field personalised healthcare initial efforts led us today delivering innovative personalised solutions help millions people around globe today phc embedded across organisation maintain clear focus entire care continuum goal making phc accessible everyone technology science constantly shifting boundaries seemed impossible yesterday may within grasp today may transform patients life tomorrow excited opportunity deliver better outcomes people around world care tailored individualpersonalised healthcare roche personalised healthcare care continuum enabled data analytics early accurate diagnosis ongoing remote care monitoring patient tailored rapid access optimal care plan interventions countries foundation flatiron health patient records medicine services available research million growth phc tests processed navify pass facts partnering deals signed companion diagnostic approvals community cancer care sites two fdaapproved flatiron health us network foundation medicine tests major academic medical centres combined power advanced imaging technology artificial intelligence large databases realworld data provides new insights diseasespersonalised healthcare roche hope future personalised cancer care canada years roche helped columbia represents important milestone lay scientific groundwork personalised transforming healthcare system canada healthcare treatments target underlying biology persons individual disease collaborative project aimed reducing targeted diagnostics help doctors fragmentation improving decisionmaking based determine right therapy patients learnings patients real time predict unlocking value advances medical science precision oncology evidence development cancer data technology towards personalised treatment programme piloting framework approach integrating help guide healthcare decision makers care people demands holistic thinking utilise rwd clinical regulatory collaboration among stakeholders across reimbursement decisions hopeful healthcare ecosystem know meaningful mean earlier precise diagnosis patients change happen work together access right treatment right time ultimate goal scale framework beyond realworld data rwd patient data british columbia provinces canada collected part routine healthcare practice also know learn predict instead clinical trials becoming may translate beyond borders roche increasingly important fill gaps capture affiliates worldwide insights help guide patient diagnosed treated demand rwd although much work yet done regulatory reimbursement healthcare less year predict collaboration decision makers continues grow particularly already showing signs progress patients personalised cancer therapies target british columbia diagnosed rare mutations traditional clinical trial precise testing earlier stage following evidence limited challenging collect cancer diagnosis additionally key system changes integrate data also begun allow tide turning however recent decision makers utilise predict framework partnership british columbia canada setting work already underway expand programme stage hope lead faster new disease areas geographies predict patient access innovative treatments one example partnering across technologies across many disease areas march society cocreate new approaches solutions roche canada british columbia cancer mindful urgency moment agency canadian personalized healthcare us personalised healthcare means far innovation network signed memorandum improving treatment improving life collaboration first publicprivate every person hopeful efforts collaboration personalised healthcare british area thatpersonalised healthcare roche targeting cancers unique drivers transforming patient care kissing young children goodnight every evening precious ritual treasured parents worldwide mary bodley cherishes moments cancer returned treatment success sure given allclear would around children six years ago months later discovered lump neck mary diagnosed invasive ductal grade worst fears confirmed cancer hernegative erpositive breast cancer returned received diagnosis first thoughts mary added complication time young family scared cancer returned evolved began telling family impact would hernegative erpositive breast cancer daughters mary says recurred herpositive ernegative knew going fight finally triple negative thankfully genomic determined see communions testing able provide treatment options confirmations hear first boyfriend could work well marys tumour girlfriend ive gone several different treatment mary lives county dublin ireland paths theyve kept alive six currently sick leave role internal half years says genomic testing huge communications manager roche ireland part current treatment working firmly believes reason able well cancer tumours stable progress far friends suggestion moment look genomic profiling roche celebrates year anniversary genomic profiling helps doctors tailor treatment mary says hope next patients unique tumour based individual years roches fantastic people fingerprint process detect tissue created rolled medicine cure blood sample mutations cancers dna forms breast cancer also hope may driving growth identify specific bulletproof method preventing breast cancer treatments target individual tumour created could implanted allows doctors refine tailor treatment women age based mutation rather location cancer body incredible work given precious extra time grateful round successful treatment mary still kiss two girls goodnight every given allclear two years later eveningaccess healthcare roche access healthcareaccess healthcare roche striving improved access healthcare around world roche know lifechanging innovation meaningful reaches need also understand millions patients world still access quality healthcare multiple barriers continue stand way know every country different situation situation exacerbated healthcare systems present unique ongoing pandemic contributing challenges draw breadth expertise increasing global inequalities innovation spans patient journey work closely many partners develop second year covid pandemic deliver tailored access solutions reflect healthcare systems around world experienced countrys individual healthcare needs significantly increased pressure throughout time continued work closely ever important urgent governments healthcare providers laboratories us acknowledge shared responsibility regulatory authorities organisations around build resilient sustainable healthcare world increasing production systems believe comprehensive uhc helps critical diagnostic tests medicines support stable economies strong societies also helping strengthen healthcare systems fundamental addressing inequality support fight pandemic access healthcare particularly lmics minimise impact parallel worked accelerating ongoing efforts area help improve access quality healthcare goal double number patients receiving noncommunicable diseases provide innovative therapies low lowermiddle noncovidrelated diagnostics treatments income countries end remains delayed even cancelled ambition double patient access novel highmedicalvalue diagnostic solutions people access strategy remains focused addressing around world root causes global country levels work collaboration global local tailoring solutions lmics un sdgs stakeholders focus pricing access around worlds population lives lmics programmes particularly low middleincome long committed lmics countries lmics support efforts range programmes broaden access achieve universal health coverage uhc medicines diagnostics countries put access centre business believe harnessing new technologies consider key part commitment healthcare improve patient outcomes including improving patient outcomes bring settings limited resources material topics innovations patients look deeply using digital solutions navify digital longterm mindset causes prevent access optimal healthcare pathology help virtual diagnosis availability healthcare screening diagnosis treatment train pathologists virtually particularly valuable regions limited pathology services key organisations active fight africa also developing new tools tuberculosis support patients taking active role continue strong partnership disease management example city cancer challenge ccan joint mission created ithemba life mobile health improve access equitable quality cancer application delivers hiv viral load results care cities around world december education reminders support directly users ccan working cities reaching smartphones app empowers people living estimated million people brings hiv remain adherent treatment engaged together health professionals care extended functionality institutions global partners cover cervical cancer address key challenge around world loss followup us genentech patient foundation provides free medicine approximately programmes partnerships support people year access along patient journey partnership echo institute strengths pharmaceuticals diagnostics working establish remote telementoring position us play early role patient programme health workers underserved journey identify barriers access rural communities enabling diagnose learned great deal partnerships treat patients faster effectively apply learnings future initiatives echo platform connects national centres excellence remote areas roche examples programmes partnerships setting echo clinics various countries expanded global access program philippines indonesia pakistan india malaysia include sarscov pcr testing increase guatemala canada first nations access low middleincome countries population several already launched ongoing pandemic roche officially joined go partnership awarded world health established innovative organizations prequalification hiv publicprivate partnership hcv tests guidelines include us presidents emergency plan aids relief cobas mtb cobas mtbrifinh tests pepfar george w bush institute unaids cobas systems patients living merck go committed creating areas limited healthcare resources healthier future women aims reduce prequalification ensures access highest new cervical cancer cases among quality diagnostics women living hiv african countries diagnostics division continued partnership nonprofit organisation red shared responsible approach medicine pricing mission emphasise importance diagnostic endeavour ensure affordability testing fight covid barrier access take pricing ongoing hivaids epidemic mitigate medicines innovations seriously impact covid health systems pricing strategy reflects whos definition fair order reach patients access limited pricing balancing need affordability roche joined world economic forums ending incentives innovation needs workplace tb initiative coalition companies patients today tomorrowaccess healthcare roche long committed low middleincome countries order broaden access medicines diagnostics like healthcare stakeholders believe differential pricing effective solution address affordability constraints specific country international differential pricing idp approach allows local organisations adjust prices reflect countrys relative income ability pay ensuring innovations fairly priced reach patients need approach proven greatly improve patient access innovative medicines particularly developing countries price primary barrier partnering improve access womens health work womens health exemplifies tailored approach access roche committed womans health every stage life supporting needs around reproduction fertility pregnancy well disease prevention treatment variety diagnostic screenings monitoring assays innovative medicines efforts support improve womens health aligned years milestones whos global strategy womens childrens adolescents health every woman every child movement revolutionising care people living hiv since entering diagnostics space roche strong key example commitment work focus infectious diseases following identification hiv womens cancers breast gynaecologic forefront developing diagnostics cancers efforts combat cervical cancer hiv particularly molecular tests early infant diagnosis viral work countries strengthen load testing monitor treatment response revolutionised healthcare systems help establish national management care hivpositive patients cervical cancer programmes eliminate disease annual cervical cancer enable equitable access hiv testing resourcelimited settings deaths occur lmics helping support unaids targets roche created global access overcome barriers care specifically program programme roche provides sustainable increasing awareness around screening roche pricing governments funders works partners build collaborating partners help countries infrastructure capabilities required run diagnostic programmes implement national hpv screening treatment year million people africa use viral load testing programmes please see story manage hiv infection date million babies tested hiv roche tests across asiapacific region hpv continues responsible majority cervical cancer cases countries cervical cancer support programmes around world aimed increasing access diagnostics treatments breast cancer copy nd spread second common cancer august apec roadmap promote sustainable economic advancement women cervical cancer prevention control officially endorsed members asiapacific economic cooperation apec roche contributed development new roadmap include cervical cancer screening especially using hpv molecular testing breast cancer overtook lung cancer worlds commonly diagnosed cancer responsible one six cancer deaths among women line new global breast cancer initiative focus womens health increased number people treated perjeta china august august uk also seen breast cancer patients switch phesgo subcutaneous fixeddose combination perjeta herceptin shorter less invasive mode administration reduced number patients receive medicines via intravenous infusion freeing capacity hospitals towards better access future looking forward work expand access continue priority working partnership stakeholders across healthcare spectrum governments payers nongovernmental organisations multilaterals insurance companies continue develop tailored solutions help overcome barriers create rapid broad sustainable accessaccess healthcare roche women cancer hepatitis c diagnosis kenya pakistan roche supporting empower programme partnership supports seeks contribute prevention early diagnosis underprivileged people treatment education women community hepatitis c testing diagnosis breast cervical cancer access projects bridge around world latam initiative implementing pink consulting rooms national programmes aimed colombia cervical cancer elimination address problems around breast cancer diagnosis treatments roche supported set cervical cancer screening triage pink consulting rooms testing one thailand million women diagnosing support thailands goal eradicating cervical cancer roche partnering government healthcare community raise awareness hpv dna testing including chile peru mexico working collaboration healthcare systems partners key resolving critical access barriers therapiesaccess healthcare roche tackling healthcares greatest challenges womens health roche challenge done curb spread life entire healthcare systems bring lifechanging threatening diseases roches cobas solutions patients across globe instruments used covid testing society expects us used cervical cancer screening come work every day relentlessly could game changer looking towards needs tomorrow hope could allow countries would one day vision brighter healthier world infrastructure place prior pandemic become reality passing year brings utilise machines help address significant new challenges including access diagnostics gaps womens health treatments diseases like cervical cancer lifechanging innovation impactful cervical cancer cases result reaches need global human papillomavirus hpv sexually cervical cancer deaths occur middle low transmitted infection vaccine already income countries diagnostic discrepancies exists despite almost preventable disparities prevalent vaccination screening approximately adjusted focus develop women succumb disease every deliver advanced diagnostic solutions year making one common causes also address significant disparities cervical cancer death women cancer especially regions burden disease peak roche added hpv many countries moving hpv dna testing screening global access program make effective efficient disease cuttingedge diagnostic solutions available prevention strategy fact world health women greatest need organization recently endorsed firstchoice method cervical cancer screening world watching waiting advances recommended clinical guidelines also made womens health july evolving favour hpv tests firstline primary announced updated screening guidelines screening supported interest improve help realise goal eliminating cervical outcomes availability technologies cancer diagnostics division remains help laboratories achieve efficiency scale committed investing advancements need meet demands highvolume significantly improve prevention strategies cervical screening programmes provide women protection care deserve empowering women take control rapidity scale comprehensive health lies core ambition testing portfolios developed transform healthcare progress pandemic left many wonder could made know still hpvassociated cancer statistics centres disease control prevention fact sheet cervix uteri world health organization recommends dna testing firstchoice screening method cervical cancer prevention world health organizationaccess healthcare roche words save lives agns kraidy journalist activist abidjan cte divoire also breast cancer survivor campaigning every woman access diagnostics medicines information felt lump left breast small public health system part clearly noticeable agns explains knew current work government herceptin something wasnt right immediately went free herpositive breast cancer patients company doctor get checked aithough nonsurgical treatments available happy basic diagnostics doctors recommended mastectomy need biopsy something even realised like many women cte divoire sophisticated ensure treated little information knowledge correctly agns asks simply breast cancer despite fact enough healthcare professionals wellequipped disease affects approximately women hospitals number patients need country year half diagnosed surviving geography also prevent access cte divoires oncology centres mostly located giving hope changing perspectives abidjan means long journeys high ultimately agns didnt go ahead accommodation costs anyone living outside mastectomy determined city centre yet another obstacle women cte divoire needed learn people simply afford costs dreadful illness want able many months treatment says agns share knowledge others affected therefore roche supported setting also wrote book journey new oncology centre bouak bring lessons ive learned along way unsurprisingly screening diagnosis followup closer tu fous les boules vaincre le cancer living parts country catalyst large awareness campaign across country words save lives partnerships many people power obstacles every step patient journey create solutions barriers patients face despite awareness raised thanks often dont wish challenge status quo agnss efforts people cte divoire still face call cancer ignorance agns multitude barriers access diagnostics advocating ongoing investment awareness treatments deserve one campaigns patient support programmes barriers affordability treatment well partnerships across different sectors reimbursement policy cancer treatments since close collaboration despite numerous challenges agns looks government roche helping increase positively future thankful access highquality care across country improvements already made focus instance first agreement made continues save lives national programme cancer provides continue overcome barriers bring effective free testing herpositive breast cancer solutions patients everywhere cte divoirepeople culture roche people culturepeople culture roche rocheproud pandemic changed many personal professional routines also reaffirming connection shared purpose strengthening sense belonging pride working roche happiness engagement people know important role play critical fundamental success global supplier healthcare solutions conducted biennial global employee opinion even evident throughout covid survey geos seventyeight percent pandemic business continuity roche employees participated survey circumstances carries higher expectations shared happy working roche results especially satisfying throughout took special care consider survey followed implementing adequate onsite safety measures particularly intense period underwent critical protect employees across research purposedriven transformations maintaining development manufacturing global supply relentless focus ongoing business initiatives chain also worked diligently ensure time worked ensure safety everyone global support functions remained supportive people patients particularly working customer premises face covid pandemic likely exposed virus health safety employees always ongoing pandemicrelated paramount also key maintaining reliable challenges faced many unpredictable supply medicines diagnostic solutions difficult situations nevertheless people patients customers need remained highly engaged evidenced score committed going extra mile ensure unchanged geos aspects work including workplaces survey results keep roche top quartile well thirdparty manufacturers suppliers global healthcare industry according remain safe healthy geos benchmark validate continued efforts sustain great working environment unprecedented times mental physical wellbeing employees demand clear survey people greater focus help support aspects happy working roche enjoy inclusive put number assistance programmes rewarding culture feel optimistic place programmes provide guidance un sdgs future positive impact patients working home mental health nutrition ergonomics social wellbeing sleep fitness focus safety wellbeing mindfulness resilience people company committed serving global live well week september material topics needs patients society employer renowned keynote speakers shared insights talent attraction committed providing safe inclusive resilience friendship happiness also retention working environment enables people offered multiple complementary activities organisational agility grow thrive reach full potential onsite virtually ranging online yoga patient centricity culture peoplecentred purposedriven fitness classes day resilience challenge diversity inclusion work culture ensuring employees thrive another critical aspect culture providing deliver best work also inclusive work environment authenticity remaining true respect inherent sense belonging employees feel comfortable presenting nurtured ensure maintain environment choose confident explicitly emphasised diversity inclusion protected discrimination based di crucial part roches history gender culture race sexual orientation cultural identity aspect free focus best work ensure measure introduced updated di vision accurately integrated inclusion strategic pillars also established di index geos council oversees strategic overall society advancing positive change society governance di ensures di properly pillar foster supplier vendor integrated business strategies diversity invest stem science technology engineering mathematics activities inspire updated di strategy focuses four pillars support future talents patients addressing unmet needs diverse patients communities additionally senior leaders demonstrated specific activities pillar include diversity strong engagement di individual clinical trials inclusive research one example di commitments shared across empacta evaluating minority patients organisation actemra first global phase iii covid clinical trial designed specifically enrol patient course year celebrated di populations often underrepresented multiple events activities including clinical studies disproportionately choose challenge campaign affected pandemic launched connection international people building workforce reflects womens day iwd continued throughout societies serve year campaign called participants pillar increased data transparency call gender bias inequality celebrate released gender pay equity report based womens achievements included photo organisationwide analysis taking challenge encouraged roche employees consideration global grading job structure level raise hands show solidarity iwd organisation etc found significant challenge status quo greater gender difference pay men women equality world similar jobs accordance united nations sustainable development goal number pride month june another highlight five achieve gender equality empower celebrated affiliates around world women girls continue commit roche switzerland awarded advancing opportunities lgbtiq certification swiss lgbtilabel women within organisation notably organisation certifies swiss companies increasing proportion female leaders advocate internal equality lgbtiq executive positions additional communitypeople culture roche proud inclusive work environment authenticity respect inherent sense belonging nurtured di month november brought together employees across organisation intensify commitment diversity inclusion employees could choose virtual events inspiring discussions engaging sessions unconscious bias training advancing inclusive research health equity neurodiversity many recognise value uniqueness individual regardless gender race age skin colour religion marital status sexual orientation heritage physical mental ability roche ever tolerate discrimination shape form furthermore firmly condemn type harassment mental physical sexual infringement violating employees right dignity respect workplace stance di strengthened updated employment policy deeply convinced success depends talent performance dedicated diverse workforce moreover strongly believe potential every single employee remain committed unlocking potential people bring purpose life living new ways working creating truly diverse inclusive workplace living new ways working directly impact ability achieve longterm ambitions deliver purpose patients need next believe greatest ideas arise collaboration cocreation asking tough questions exchanging perspectives challenging also shifting paradigms capable innovating developing lifechanging solutions increased use technology digitalisation introduced number new approaches tools provide people aroundtheclock support rapidly changing environment prompting us think differently sustain competitiveness stranger change capacity adapt undergo transformations dna since founding years ago reinvented advanced science technology adjusted ways working multiple times throughout history recent implementation agile working methodologies operating models boosted speed efficiency deliver solutions patients healthcare providers pandemic forced physical distance among many us also revolutionised ways working making us much agile collaborative roche continued broad transformation journey despite confusion uncertainty created pandemic people never shown engagement dedication cocreating future shaping years milestones healthcare systems throughout challenging times alice keller shatters glass ceiling alice keller talent talent emil c barell ceo roche evolving ways leading recognised brought company new ways working go hand hand feeling brilliant people care much convention new ways leading every roche employee times whether man woman matter champion deserves work thrive great leadership excellence form operating seven leadership commitments many years posted alice position japan day journey time role leaders boat arrived tokyo handle countrys product launches evolved continues correspondence basel alice loved japan unsurprisingly excelled role within three years promoted director past several years continued roche japan making first woman senior executive roche utilise kinesis synergy senior leadership sensational development time development programmes pandemic forced us rethink way organise run women like alice paved way inclusion people diverse programmes events instance global backgrounds experiences skills perspectives key virtual leadership development initiative success today future launched virtually incidentally gave much broader audience access valuable toolpeople culture roche implementation agile working methodologies operating principles boosted speed efficiency deliver solutions patients healthcare providers become agile need shift towards shared leadership one fosters trust ownership becomes evident developing networked organisation decisions longer made silos due high interconnectedness interdependence across company approach requires leaders apply vacc principles visionary architect coach catalyst leading serving teams organisation vacc leadership approach aligns creative mindset supports cocreating vision allowing us achieve results actively authentically drive change enable role models continuously push learning empowerment unique efforts investments developing coaching skills leaders recognised international coaching federation icf autumn awarded icf prism award special mention award recognises roches approach making coaching integral element leadership culture fulfilling highest professional standards creating measurable positive impacts introduced number new approaches tools provide people roundtheclock roche want everyone build capability support additionally set broad range lead learn encouraging selfleadership internal external training learning fostering learning mindset help opportunities designed strengthen people thrive achieve refined foundations agile selforganised workplace existing people development strategy provided portfolio activities training support business function people culture also selfgrowth individual leadership undergone significant transformation refreshed workforce strategies revamped enhancing everyones experience organisational growth efforts updated unveiled new approach engaging core processes practices thanks developing employees years ago efforts people culture set goal becoming agile organisation become efficient strategic partner took significant step towards increasing also established new standards use technology digitalisation improve creation value longterm success employee experience organisation throughout pandemic provided tailored resources support employees working home including ergonomic assessments occupational health safety pandemic continued impact operations roche however manufacturing related activities kept running time countries due decreasing case numbers operations resumed onsite least temporarily countries employees continued work remotely sites managed pandemic locally using uniform riskbased approach mitigate likelihood workplace transmission offered sarscov testing many cases vaccination employees working onsite home sites provided tailored support resources employees working home consisting information programmes maintain health wellbeing support setting ergonomic working environment home remote access employee assistance counselling roche actively supported possible community employee health safety programmes deliver vaccines provided upto date evidencebased information dismantled barriers employees get vaccinated sarscov influenza one primary objectives provide safe workplace employees offsite occupational accidents include operating motor vehicles present significant risks roche actively managed part risk management programme included current set goals aim continuously improve safety employees goals keep roche accident rate rar rar corresponds number working days lost due occupational accidents per employee per year reduce vehicle collisions per million kilometres losttime illness rate roche accident rate working days lost per year due accidents number workrelated accidents roche accident rate threeyear averagepeople culture roche employees region africa north america asia parttime australianew zealand fulltime latin america europe total workforce pharmaceuticals management diagnostics bod chugai cec corporate others women employees odg number employees expressed fulltime equivalents based headcount excluding chugai due arms length alliance agreement roche majority shareholder chugai retain autonomy operating divisional grouppeople culture roche lifelong career roche hans aeberhard embarked roche apprenticeship basel could imagined would eventually retire company years months days hans grew basel common switzerland people strove discover develop teenagers complete short apprenticeship potential hanss colleagues close final year school deciding heart met lot people shared career although concrete vocation experience expertise helped grow mind hans knew profession explains fact many colleagues something technical offer good prospects become friends growth development choice become chemical technician influenced challenges teachers enthusiastic career handful opportunities existed roche older challenges hardest reorganisations brother started apprenticeship often involved downsizing difficult chemical technician years earlier also sustain highperforming team approved happy path chose department gets reorganised says especially hans says job never boring able say goodbye great people develop professionally personally work innovative environment past two years pandemic challenge manufacturing sector highlights well hans wife however working looking back plenty highlights fill home period provided way hans pride fond memories deep ease retirement august appreciation roche familyowned generations leadership convinced new chapter life reflected culture employees years advice hans offer always treated respect colleagues successful fulfilling career perseverance managers alike dont give things get tough authentic speak know hold back working cutting edge innovation explains lastly team player respect technology always key motivator colleagues pioneers liquid crystal technology mids set stateoftheart fully looking next years hans hopes computerised manufacturing building campus roche sustain unique legacy keep early years digitalisation employees patients core hopes family stay personal highlights include promotion happy healthy although retired hans foreman becoming line manager leading fully disconnect profession people job personal sons decided follow footsteps commitment developed genuine interest become pharma technologistsenvironment roche environmentenvironment roche environmental protection going beyond achievements known today safety security health environmental protection roche conceived industrial accident roughly years ago blast one subsidiaries italy reputation audits consulting training known today seveso incident resulted culture combined professional release toxic chemicals air risk management system minimise risks aftermath incident brought expert teams roche site identify risks standardisation industrial safety regulations develop mitigation plans communicate would greatly influence future policy guidelines employees roche beyond stakeholders support implementing necessary measures seveso incident tragic also huge opportunity roche evolve many environmental challenges approach environmental protection since occupied us last years include late protecting environment waste well emissions air water integral part operations approach today climate change forefront sense responsibility changing climate introduced new risks methodically issues concerning resource scarcity heightened occurrence quality productivity cost efficiency wherever natural disasters roche operational possible economically viable strive risk management strategy includes forecasting continuous improvement seek evaluating financial implications sustainable longterm improvement changing situations extreme weather water behaviour adapting equipment scarcity could operations recent standards developing innovative processes throughout organisation order developing environmental ensure disasters like seveso incident protection goals since current fiveyear recur devote special attention prevention goal period runs goals un sdgs reducing risks key effective set areas people environment environmental management business challenging achievable managing professionally proactively company production operations around maintain current high levels world roche exposed risks could performance standards across possibly damage people goods environment organisation material topics energy efficiency longterm mindset embracing environmental responsibilities environmental responsibility guided roches offer supply chain partners renewable activities many years started reporting energy combined competitive rate greenhouse gas ghg emissions early used project research gauge since implementing receptiveness suppliers offered carbon dioxide reduction measures led actively support sustainability journey combined decrease carbon dioxide providing commercially valuable solutions generated within operations scope monitoring results determine purchased energy scope strategies extended offer highspend highemission suppliers representing however operations impacts roches spending uk well extend far past company gates purchase smaller diverse suppliers materials components services enable us develop manufacture products another area focus partnerships patients need form part concerns reuse materials number environmental responsibilities collaboration projects established completed total ghg emissions inventory suppliers understand opportunities includes emissions associated reduce levels waste including plastic interactive goods services purchased roche workshops held key suppliers focused extend focus hot spots within singleuse technology filters looked supply chain develop mitigation strategies ways recycle reuse substitute materials benefit environment minimising carbon footprint parallel bring future sustainable longterm financial reputational benefits electricity comes roche suppliers sustainable sources continual pursuit reduce ghg emissions scope supporting suppliers scope sources developed clear effective managing extended ghg defined process generate progress setting responsibilities identified best ways challenging realistic goals developing action work different segments supply plans achieve goals base identified suppliers across implementing pharmaceuticals diagnostics divisions whose products services account nearly scope programme also constantly evolving onethird total carbon footprint engaging new innovations become available suppliers active dialogue working next months finalise scope carbon develop sustainability reduction strategies set targets based strategies partnership also encourages potential reduction extend number greater transparency better decisionmaking suppliers actively collaborate outline expectations longerterm ambition support suppliers efforts gradually move towards productspecific decarbonise operations processes one reporting suppliers used strategies involves pilot project monitor carbon dioxide reductions inform partnered ukbased energy supplier product choicesenvironment roche committed sustainable energy future implementing innovative technologies improve energy efficiency also using power people drive change across roche everyone voice heard everyone contribute sustainability efforts sharing ideas innovation platform touch aspect sustainable development agenda whether environmental social including human rights economic refreshed supply chain sustainability council internal decision making body executive level reviews ideas business cases decide ones resource implementation support level focus prioritisation sustainability within business allows ideas concepts turned impactful deliverables widescale change scope strategy execution centres three key themes reducing reusing recycling involves influencing business travel steering towards sustainable energy future behaviours reducing spend nonessential goods services recycling reusing materials roche recognises climate change one largest global risks substituting innovating addresses matter urgency expert teams problemto involves substituting nonsustainable solutionfocused mindset addressing global issue energies sustainable energies considering years greenhouse gas ghg emissions roche originate environmental stewardship product designs transformation use energy instead compensating alternative logistics methods routing offsets teams pursue programmes actively reduce ghg emissions engaging partnering suppliers priority include reducing energy consumption increasing supply chains energy efficiency substituting energy sustainable involves transitioning suppliers towards sources measures already reduced ghg emissions renewable electricity incorporating since basel kaiseraugst site example sustainability core element global supplier energy consumption buildings operations minimised relationship management strategies innovative design heated waste heat heat environment carbon dioxideneutral way continue optimise recognise deliver sustainable energy use throughout company striving towards one goals supply chains alone build reducing scope ghg emissions zero existing industry collaboration extend reach influence learn industries approaches sustainability environmental performance data continuously monitoring environmental impact approximately puts us performance aim collect data clear path reach least key performance indicator ensure compliance high committed contributing sustainable standards objectives guarantee energy future make vision reality processes equipment state art since implementing innovative technologies improving shown progressive improvement energy efficiency increasing use reducing environmental footprint roche sustainable energy considerations positively measures environmental impact using eco impact environmental footprint example balance metric measures environmental dramatically reducing ghg emissions impact pollutant emissions resource extraction activities ecopoints per unit quantity greenhouse gas reduction efforts points added related total number success reducing energy consumption employees enables us monitor carbon dioxide emissions credited environmental impact per employee taking business roches ghg management approach growth account since reduced example diagnostics site meylan france became first roche site reduce ghg emissions stationary sources eg heating purchased electricity zero site consists new energyefficient building provided electricity sustainable sources well biomethane site focusing car years milestones fleet strategy optimise emissions former nutley site embodies roches legacy three roches technical production sites roche takes environmental responsibility seriously determined heating ventilation air conditioning systems create longterm social value communities nutley remediation cleanrooms optimised areas project exception nutley site closed roche utilise high ventilation rates meet room air quality committed making sure acre former us headquarters requirements optimisation reduced carbon carried legacy innovation social responsibility dioxide emissions approximately tonnes per year resulted annual monetary savings pioneering approach environmental investigation remediation approximately chf project novel divestment strategy cut years traditional timelines expanded pharmaceutical production attracted developer property sold roche sites estimated monetary savings retaining responsibility site cleanup increase approximately chf million per year maximum reduction carbon dioxide called campus boasts research institutions private emissions tonnes per year clinical laboratory approximately employees compared site closed tenants include healthcare biotech similar ghg reduction measures place retail hospitality leaders vision contributing part fiveyear goals sustainable areas economic social wellbeing generations come energy future activities result reduction carbon dioxide emissions scope sourcesenvironment roche water consumption noise pollution energy consumption landfilled waste emissions water emissions air roche ecobalance stipulate company car fleets consist vehicles use less mjkm vehicles operate using energy sustainable sources grid electricity company vehicles first priority reduce usage energy energy use energy use look ways improving efficiencies heat recovery selected types addition encourage use renewable business air travelling energy wherever makes sense natural gas video teleconferencing facilities established sites widely used employees encouraged use trains consolidate several business trips one scope scope capital goods scope scope scope ghg emissions ghg emissions ghg emissions co co co purchased goods scope scope services scope fuel energyrelated activities transportation distribution waste generated operations business travel use sold products sustainability top priority sites kaiseraugst switzerland example energy consumption buildings operations minimised innovative design direct emissions within operations indirect emissions purchased energy emissions resulting activities within supply chain verified methodology based ghg protocol environmentally extended inputoutput model due methodological inaccuracies evolve complemented refined data becomes available numbers serve baselineenvironment roche energy consumption terajoules total scope scope energy scope scope consumption gjemployee gj gigajoule halogenated hydrocarbons tonnes inventory releases global inventory including chugai genentech ventana includes data additional roche sites well wider scope halogenated hydrocarbons previous years emissions air tonnes vocs particulates nitrogen oxides sulphur dioxide volatile organic compounds water usage discharge water withdrawn million water consumed million organic matter discharged waterways treatment heavy metals discharged waterways treatment kg landfilled incinerated waste tonnes nonhazardous hazardous contaminated soil hazardous construction waste nonhazardous less contaminated soil removed due reduced remediation activities kesslergrube germany increase hazardous waste due reallocation electronic waste hazardous waste environmental data spark therapeutics flatiron health foundation medicine included roche environmental resultsenvironment roche managing risks people environment assets peter schnurrenberger team evolved safety security health environmental protection function become integral part business activities past years driven strong belief protecting people quantity also quality water matters environment assets integral society becoming less accepting nonnatural success company betterment chemicals water know need society peter team developed reduce pollution chemicals comprehensive management system particular readily decomposable embedded throughout organisation possible need transparent core pillar business associated risks versus benefits societal expectations increased time standardising information another area focus reflected laws regulations roche transparent regarding people realise ever reporting also advocating harmonised must act protect planet reporting systems know society benefit future generations says peter know increased knowledge reassurance despite progress made today see standards drifting apart becoming still opportunity improve far complex detailed thus creating lot bureaucratic burden questionable value looking towards future peter sees relative effort says peter need work number key issues must tackle stakeholders create simple informative organisation obvious area climate change robust reporting framework says want reduce associated risks need bold action roche set goal finally increasing global dependencies eliminate greenhouse gas emissions risk events widespread impact increasing developing roadmaps towards goal well global healthcare company need action plans implemented across well prepared situations must areas business faster act less ensure uninterrupted supply products greenhouse gases atmosphere patients peter says responsibility patients society driving force behind another key issue water basis activities taken lightly end life indispensable basic material day know order achieve goals manufacturing pharmaceutical diagnostic need educated highly committed passionate products water scarcity increasing several people driving efforts lot regions around world need work done responsibility clean water must reduce water move activities forward order protect consumption reuse recycle wherever health safety wellbeing generations feasible peter reflects comecommunity engagement roche community engagementcommunity engagement roche community impact lasting tradition philanthropy roche years remained committed making sustainable difference communities operate beyond part commitment society first longest philanthropic partnership local nongovernmental organisations ngos international committee red cross support early childhood development icrc began supporting icrc education efforts around world effort help displaced hungry across europe years partnership response pandemic related restrictions icrc continued evolve grow gatherings employees got creative un sdgs reinvented event include wide range became founding member innovative fundraising activities icrc corporate support group since events included plogging combination jogging supported icrcs access water initiative picking litter south korea volunteering mali total one million people benefited orphanage cte divoire walking meeting programme proud many challenges spain virtual boxing workshops enduring partnerships organisations like colombia total people icrc collaborative efforts make sites across countries participated difference communities around world fundraising activities partnerships core pillars take every year colleagues nominate employee longterm approach philanthropy ambassadors visit react childrens projects wellestablished strategy maintain clear witness firsthand impact focus engagements philanthropic fundraising activities group nine strategy built around four pillars community ambassadors made virtual visit childs dream projects supporting arts investing reacts newest partner ngo focused education providing humanitarian support childrens education southeast asia strictly adhere specific criteria throughout partner project selection processes visit ambassadors chance criteria include quality innovation meet founders childs dream see sustainability schools computer labs helping build cambodia hear directly students grassroots community engagement scholarships changing biggest employee engagement lives meeting person ideal virtual philanthropic event roche childrens walk immersion truly inspirational money event began employeedriven saved travel went local childrens ngos material topics pilot project across sites basel nutley ambassadors respective countries learn longterm mindset palo alto funds raised walk childs dream please see story availability healthcare go react independent global charity art means connect communities young commissions engage new contemporary long history supporting groundbreaking classical composers expose scientists contemporary art cultural projects included leadingedge experiences sound explorations parallels innovations art innovations science exposure new one young composers australian ideas perspectives helps foster culture born kirsten milenko debuted new piece traho openness creativity roche also helps pays homage unfathomable losses australia promote diversity inclusion celebrating experienced result wildfires raged different cultures disciplines resulted loss billions animals millions hectares began collaborating lucerne burnt land piece musicians sang festival international festival contemporary tribute perished helped classical music unique project called roche keep memory alive public mind commissions every two years commission new orchestral work one worlds nationalities represented roche talented composers starting committed diversity inclusion partnership extended include roche support projects like culturescapes multidisciplinary swiss festival promotes crossborder cultural dialogue helps us celebrate diversity bringing unique facets employees years milestones culturescapes focused amazon region bringing artists brazil colombia peru good clean health south africa ecuador switzerland topics explored phelophepa means good clean health sotho million festival included climate change access people rural south africa meant access affordable primary water violence peace collaboration healthcare roche transnet freight logistics company festival wideranging roche phds came together establish phelophepa worlds first comprehensive postdocs employees latin america primary healthcare facility rail access performances workshops artists started threecar train expanded two coach trains provide range healthcare services including dental bring benefits event many ophthalmological psychological general health main external people possible roche brazil hosted virtual sponsor roche provided additional support covid pandemic culturescapes week throughout week including protective sanitising equipment shared music artists provided transnet launched third train support phelophepas covid response people vaccinated patients received basic healthcarecommunity engagement roche one roche young commissions recipients kirsten milenko following debut new orchestral work traho ib sales shaman indigenous huni kuin people brazil performed burned instruments orchestra culturescapes amazonia mind body workshops offered talks social issues artists exploring work extended workingfromhome period event provided valuable outlet connecting colleagues creativity exploring diversity inclusion new way feeling sense pride engaging roche philanthropy getting students excited stem roche science technology heart committed supporting interest disciplines among young people international local programmes improving access education realworld science technology hope support next generation innovators years roche supported swiss youth science promotes science technology among young people became founding sponsor international swiss talent forum organisations think tank programme annual meeting brings young people around world together discuss current global issues also proud support host science move switzerlandwide school competition run biennially cooperation simplyscience foundation ten schools participating presented projects theme smart systems jury roche scientists academics industry experts winning class take sciencethemed trip london healthcare workers volunteers days fund ngo committed reducing childhood stunting indonesia showing mothers impact poor nutrition childrens health roche helped establish countrys first impact stunting centre excellence goes without us healthcare company committed building stronger healthier communities supporting human social services systems places needed seek partners aim implement simple meaningful measures result lasting improvements sustainable impact society example supported days fund indonesia established help reduce childhood stunting condition defined shortness height childs age arising prolonged malnutrition affects physical cognitive development support ngo established countrys first impact stunting centre excellence provides tools training community healthcare workers parents three additional centres opened directly benefiting people including healthcare workers parents children addition model garnered support ministry health attracted new donors enabling continue scale integrate healthcare system ensuring sustainability project including ability go without us central philanthropy roche another sustainable way supporting communities global philanthropic secondment programme allows roche employees volunteer ngo supporting global health education walter lee roche diagnostics see photo supported terre des hommes childrens aid organisation defining model introduce new global health technology digital stethoscope low middleincome countries improve outcomes childrencommunity engagement roche international committee red cross supported icrc years became founding member icrc corporate support group contributed water habitat activities several countries across africa one million people benefited access water initiative mali childs dream world wide fund nature working childs dream recent react partner improve education wwf cofounded dr lukas luc children southeast asia hoffmann grandson roche founder fritz hoffmannla roche wife adle roche students benefited new continued support wwf ever since classrooms computer labs scholarships partnerships cambodia people benefited rebuilding efforts nepal kenya zimbabwe achieved together unicef swiss youth science working together support access education children disadvantaged backgrounds several countries throughout africa supporting swiss youth science asia seeks promote science technology young people years children benefited educational programmes across ethiopia malawi students reached nepal philippines swiss youth science programmes phelophepa healthcare trains main external sponsor phelophepa free mobile healthcare clinic travels rural areas south africa since first journey years ago million people benefited basic healthcare services trainings jobs phelophepa south africacommunity engagement roche balance heart head helped childs dream become reality marc jenni daniel siegfried gave careers banking set charity children asia started nothing built association delivers health education perhaps important hope good philanthropy requires perfect balance marc sat little guest house front heart head heart needs blank piece paper night really understand care people ideas formed happy trying help head must stay developed something meaningful rational make good decisions productive partnership daniel talking secret success organisation established partnership childs dream charitable notforprofit roche three clear areas focus organisation supporting children young cambodia improving school building infrastructure adults myanmar laos cambodia thailand fiveyear goal new primary secondary cofounded marc daniel high school classrooms benefiting students organisation employs people year supporting computer laboratory facilities work reduce childhood mortality improve aim ten fully equipped computer health hygiene schools communities laboratories vastly improve skills also increasing access quality education knowledge finally backing high school scholarships help marginalised students improve marc daniel admit balance job social mobility opportunities always easy maintain current situation myanmar particular absolutely devastating partnership works shared says daniel making really difficult purpose roche engaged work become emotional lose balance says daniel impact real last years managed provide new school buildings thousands navigate line deliver meaningful change children cambodia real hope thousands children marginalised difficult backgrounds computer labs comes digital literacy meaningful mission important bring new opportunities set childs dream successful unfulfilling careers banking switzerland hong emphasise make difference kong singapore experiences provided mean travelling side gateway southeast asia first realisation world mean social worker challenges faced local children network whether thats family members two realisation pivotal neighbours local community try moment daniel basically epiphany maintain balance heart head wanted something meaningful says marc remember even biggest suggested set childrens charity says storm sun come shine againbusiness ethics roche business ethicsbusiness ethics roche integrity driver business ethics upholding high standards ethics integrity sustainability complying laws regulations making positive impact society everything roche believe integrity basis strengthen shared ethical mindset sustainable successful business start across organisation every employee responsibility behave integrity accordance fostering collaboration oneroche shared company values compliance guidelines approach commitment also reflected although several distinct businesses expectations place partners around partners within roche group know world require distributors suppliers fostering collaboration oneroche service providers meet integrity approach key overall success standards emphasise sustainability expect approach driving force behind many business partners help foster social compliance risk opportunity management economic development communities efforts operate one example initiative aimed also continue focus efforts enhancing effectiveness collaboration across stakeholders understanding trust assurance functions including limited organisation help ensure trust compliance quality safety health environment remain independent political affiliation insights comprehensive collaborative spent chf million switzerland gap analysis revealed high level competence spending included payments industry many key areas moving forward see great associations various chambers commerce opportunity continue fostering collaboration financial assistance trade unions donations across assurance functions ensure roche political parties cantonal federal levels holding highest standards providing donations political parties low pragmatic solutions business un sdgs doubledigit thousand range swiss francs ultimate goal improving patients lives together accounted approximately total contributions donations building common set values across divisions countries two examples demonstrate covid pandemic impact want move towards holistic consistent material topics work together within roche including sustainable approach compliance human rights ensure compliance affiliates worldwide ethics transparency implemented new ways working harmonised compliance risk patient centricity empowered compliance network focus opportunity management process across availability healthcare collaboration exchange allowing us divisions intent initiative improve compliance efficiencies minimise redundancies enhance formed team supplier risk transparency management professionals providing support enabling procurement team part overall review approach well rest organisation also business ethics incident management developing stateoftheart tools facilitate risk also developed new system internal non assessment management compliance case management reporting system enables stronger collaboration provide support employees working different functions involved management procurement sourcing implemented new cases especially compliance internal online due diligence tool tool provides investigations team people culture guidance mitigate risks related finance supply sustainability technology intellectual collaboration patients property quality contracts guidance along evolving improving internal based inherent risks associated processes also striving engaging type supplier expect important dialogues outside roche engage know learn great deal patients adhering stringent ethical standards key working together mitigate risks protect impactful effective interactions human rights developed supportive coaching tool roches commitment human rights reflected called compliance patient engagement navigator stringent requirements place tool supports business identifying suppliers worldwide applicable principles rules provides regard suppliers service providers robust guidance enabling roche employees partners put efforts creating build compliant sustainable relationships relationship mutual trust collaboration patients patient organisations please order ensure standards met see story one important element relationships adapting meet changing needs supplier sustainability assurance visit programme healthcare system continues transform ssav gives us ability positively rapidly must look respond effectively impact labour conditions suppliers facilities spend money late roche roche supplier code conduct binds finalised new policy thirdparty spend suppliers adhere clearly stated performance policy moved us providing tactical guidance expectations including performance human focused procurement activities providing rights allows roche conduct ssavs help rochewide principles parameters governing ensure compliance collaboration spend money new framework allows capability building suppliers evaluated us set operational procurement rules annually standardised riskbased process processes local level establishing identify high risk human rights globally applicable due diligence sustainability violations vulnerable populations children requirements underage workers migrants local underprivilegedbusiness ethics roche modern safe remediation methods kesslergrube site grenzach germany protect water nearby rhine river communities people low levels education suppliers determined high risk included ssav programme looking future essential us constantly develop expand human rights requirements guidelines order ensure continue meet highest possible standards updated methodology address industry sectors previously considered well nonorganisation economic cooperation development oecd countries performance standards may lower human rights risks associated certain commodities ensure properly addressing issue child labour also integrated unicef childrens rights workplace index methodology identifying high risk suppliers inclusion ssav programme despite ongoing challenges covid years milestones pandemic roche continued ssav programme using carefully developed remote auditing protocol adopting hybrid virtual onsite part generations come approach conducted ssavs kesslergrube site germany served emea apac north america mixed landfill domestic industrial chemical waste latam human rights related local community businesses including roche eventually area observations see graph covered authorities decided need remediation order protect local groundwater resource following every audit suppliers commit adjacent river rhine documented corrective action plan address audit finding ssav programme also includes recognising social ethical responsibility protect followup audits verify corrective actions environment generations come began one adequately address identified findings complex remediation projects germany still ongoing today going way beyond legally required goal eliminate human rights come first much existing soil groundwater contamination possible one example illustrates partner proactive approach create positive impact making suppliers help increase human rights standards remediated area available reuse effort reduce environmental impacts converting roche fleet electric vehicles work closely suppliers around world ensure adhering highest ethical standards areas business protecting human rights key efforts believe greenhouse gas reductions come expense human rights objective ensure manufacturers providing electric fleet vehicles full compliance oecd guidance responsible supply chains also able trace conflict minerals smelters refiners compliant human rights expectations accordingly suppliers electric vehicles must full compliance oecd guidance ethical mineral sourcing code conduct protects miners families recycling programme conflict minerals roche ceased negotiations electric vehicle manufacturers refuse supplier code conduct right audit equivalent sustainable supplier code conduct policy compliance business supplier refuses accept principles supplier code conduct employees used roche group speakup line operated right audit compliance external provider available languages countries sustainability principles chief compliance officer received reports alleged violations code conduct via business ethics incident reporting system unfounded founded still invqesutoigtaetio n result employment contracts agreements business partners terminated grounds unethical behaviourbusiness ethics roche general packaging administrative services excessive overtime lack labour policy practices contract research facilities maintenance human rightsrelated organisations findings per excessive overtime incorrect industry lack labour policy excessive overtime compensation overtime delayed payment wages laboratory supplies logistics transportation inadequate maintenance employee time records incorrect overtime compensation granted annual leave incorrect deduction wages patients heart everything work closely patient community listen learn integrate feedback aspects workbusiness ethics roche reflecting responsibility patients look history humbled concessions make day trust patients families placed us today lives insights guide us trusted research medicines help improve patient experience diagnostics developed integrated diagnosis treatment ongoing monitoring solutions launched help improve patient support work engage patients quality life responsibility patients right way centralised global care driving force patient partnership team worldwide patient behind approach patient partnership partnership network partner across company drive collaboration patient last years worked communities within core geographies understand gaps exist treatment diseases like cancer multiple sclerosis spinal collaboration patients culminates muscular atrophy many longstanding commitment help tried keep people impacted community network share mobilise broad diseases mind always asked health system topics international perspective value care experience exchange patient organizations years made concerted ieepo past years ieepo effort learn work become signature roche offering helps patient community integrate patient groups share learnings identify synergies feedback work markets collaborate health topics make healthcare accessible patients today take centre stage roche everyone around world also engage early systematically across opportunity patient groups tell us business ensure thinking disease well improve management shaped feedback close patient groups countries outcomes matter participating platform wwwieepocom survival relief symptoms cure disease ieepo become central vision past challenged regulatory patient partnership authorities payers outcomes measured medicines collaborative approach resulted required us take step back consult roche ranking first corporate reputation patient community refine thinking amongst peer group big pharma hope proactively getting patient announced recognition communitys perspective answer testament vision partnering right research questions upfront patients willingness share trust us responsibility beyond research patients families driven us last years one educate us live cope carry next ranking based corporate reputation pharma report patientview independent organisation based ukbusiness ethics roche integrity underpins every aspect business adriano treve joined roche years ago trainee region iran saudi arabia bangladesh pakistan cyprus past three years served area head turkey russia iran central eastern europe central asia indian subcontinent adriano passionately believes integrity noncompliance universal however vital roches cultural mindset preclude flexibility accommodate future success conduct business within different cultures long integrity preserved framework highest professionalism full example countries small gifts like compliance legal regulatory requirements chocolates used show respect business prerequisite licence operate interactions regions would vital sustainability reputation unacceptable advising team adriano future integrity extends beyond simply ensuring guided principle integrity motivation correct procedures followed must suggested form normal ingrained within culture part local business practices likely alter basis engagement business code conduct defines us stand partner even circumstances modest roche expects us core values business gifts normal must remain token courage passion integrity adriano nature cultural variance never licence explains confident managers excess colleagues respond integrity empowered express concerns integrity leadership coupled conscious trust colleagues noncompliant behaviours effort foster behaviour within teams less likely occur concern discussed crucial roche continue behave becomes issue avoided approach consistent demonstrable personal integrity adriano extended across teams ensuring consistently cultivate encourage everyone directly works feels values areas responsibility integrity able speak confidence without driven mindset makes us ideal partner around fear retaliation employees also use world allowing us serve wider groups patients anonymous roche group speakup line report compliant merely compliance concern via intranet phone required right thing adriano supports roche policy zero tolerance celebrate year anniversary adriano noncompliance draconian reflects future roche years come may sound open supportive culture means roche already futurefit living less opportunity unethical behaviours principles today guide success next emerge says concerns raised early years says important thing discussed openly actions taken continue attract talent ensure noncompliant behaviour avoided high calibre today people rooted code conduct applies across organisation roche heartland making meaningful difference regardless geography culture zero tolerance patientsbusiness performance roche business performance key figures chf millions group sales pharmaceuticals sales diagnostics sales core operating profit r core investments chf dividend growth rates report constant exchange rates cer average business performance roche diagnostics pharmaceuticals employees operating divisional group corporate others chugai research development sites manufacturing sites pharmaceuticals pharmaceuticals diagnostics worldwide diagnostics worldwide treated roche medicines million patients model list essential medicines roche medicines number employees expressed fulltime equivalents roche group group sales rose chf new sales impact competition chf billion core operating profit increased biosimilars cancer medicines avastin chf reflecting strong underlying herceptin mabtherarituxan slowed business performance core eps grew expected combined chf billion sales chf swiss francs appreciation reduction second half year saw almost currencies affected results signs recovery covid pandemic expressed swiss francs compared constant exchange rates diagnostics division reported strong sales growth chf billion divisions ifrs net income chf billion base business showed strong momentum represents increase chf throughout overall sales driven operating results totalling chf billion roches leading portfolio covid tests contributed significantly december roche completed chf billion divisions overall sales repurchase roche shares held novartis restores roches full strategic flexibility outlook retaining operational scope action sales expected stable grow lowsingle digits constant exchange rates pharmaceuticals division sales increased core earnings per share targeted grow chf billion strong demand newly low midsingle digit range constant launched medicines treat severe diseases exchange rates including accretive effect namely hemlibra haemophilia ocrevus multiple recent share repurchase roche expects sclerosis tecentriq cancer evrysdi spinal increase dividend swiss francs muscular atrophy phesgo cancer drove growth medicines treatment covid roche anticipates sales covid medicines also contributed sales growth ronapreve diagnostics decrease approximately highrisk covid patients actemra chf billion around chf billion sales roactemra severe covid pneumonia losses biosimilars current year roughly chf billion excluding overall medicines launched last effects group sales expected grow ten years contributed additional chf billion highsingle digit range un sdg material topic longterm mindset growth rates report constant exchange rates cer average launches since erivedge perjeta kadcyla gazyvagazyvaro esbriet cotellic alecensa tecentriq ocrevus hemlibra xofluza polivy rozlytrek phesgo enspryng evrysdi gavreto ronapreve susvimobusiness performance roche roche group pharmaceuticals division sales chf millions diagnostics division diagnostics diagnostics sales grew driven strong detection monitoring donor screening momentum base business continued sexual health genomics high demand covid testing point care sales continued grow sales grew strongly across world significantly sarscov rapid europe middle east africa emea antigen test main growth driver asiapacific north america especially emea region latin america customer area provides diagnostics division also seen strong sales growth solutions immediately point care across customer areas emergency rooms medical practices directly patients includes sarscov core lab sales increased due rapid tests blood gas electrolyte tests immunodiagnostics business infectious cardiac tests main contributors sales diabetes care sales increased driven grew across regions strongly emea blood glucose monitoring business asiapacific accuchek guide system customer area focuses central labs customer area focuses integrated provides diagnostics solutions personalised diabetes management people areas immunoassays clinical chemistry diabetes healthcare professionals custom biotech pathology lab sales increased molecular lab sales grew led virology mainly due growth advanced business delta variant continued push staining business growth covid testing highthroughput pcr tests sales increased regions led customer area focuses pathology labs north america asiapacific regions provides diagnostics solutions tissue biopsies companion diagnostics customer area focuses molecular labs targeted diagnostics support specific provides diagnostics solutions pathogen therapy decisions patientbusiness performance roche sales customer area chf millions core lab molecular lab point care diabetes care pathology lab pharmaceuticals pharmaceuticals division sales increased new returning patients boosted growth continued strong demand newly launched latter group generating stronger sales medicines offset impact biosimilars perjeta first approved chf billion herpositive breast cancer sales increased united states sales decreased mostly due high demand china early sales actemraroactemra hemlibra ocrevus metastatic breast cancer settings evrysdi tecentriq increased impact united states sales perjeta declined due biosimilars covid pandemic affected certain patients switched kadcyla total growth expected due launch phesgo europe sales grew growth recently tecentriq first approved chf billion launched medicines compensated cancer immunotherapy either alone impact biosimilars covid combinations various types cancer eg lung pandemic bladder breast liver cancer sales increased regions notably japan primarily due japan sales increased driven demand treatment hepatocellular strong demand new medicines carcinoma hcc us sales higher driven compensated competition biosimilars new indications hcc firstline nonsmall government price cuts cell lung cancer nsclc sales international region grew hemlibra first approved chf billion china sales stable growth perjeta haemophilia without factor viii alecensa heceptin offset impact inhibitors prophylactic treatment biosimilars excluding china sales increased administered subcutaneously weekly every mainly driven new product sales partially two every four weeks sales continued show offset biosimilars competition strong uptake especially united states europe ocrevus first approved chf billion relapsing primary progressive forms kadcyla first approved chf billion multiple sclerosis twohour infusion herpositive breast cancer sales growth demand treatment indications driven usage kadcyla early remained strong mainly united states breast cancer setting sales benefited patients pandemic still certain negative impact switching new standard treatmentbusiness performance roche topselling pharmaceuticals chf millions ocrevus neuroscience perjeta oncology actemraroactemra immunology tecentriq oncology avastin oncology hemlibra haemophilia herceptin oncology mabtherarituxan oncologyimmunology kadcyla oncology xolair immunologycorporate governance roche corporate governance principles business activities focus sustainable governance roche complies value creation innovation management relevant corporate governance requirements culture conforming recognised standards particular applicable laws swiss good corporate governance policy stock exchange six swiss exchange directives transparent communication embody roches swiss code best practice corporate corporate governance principles build governance promulgated swiss business basis successful implementation federation economiesuisse companys internal roches commitment serving stakeholders governance framework particularly articles incorporation bylaws embodies strong board directors represents principles needed ensure companys interests shareholders businesses managed supervised manner stakeholders highly skilled managers consistent good corporate governance act integrity extremely important including necessary checks balances roche ranked one top three printed annual report contains selected links sustainable healthcare companies roche website httpswwwrochecom pharmaceuticals index dow jones readers thus provided snapshot sustainability indices djsi th year company reporting date also running recognition based indepth directed sources consult analysis economic social environmental time uptodate information corporate performance djsi serve benchmark governance roche whereas annual report investors integrate sustainability considerations covers single financial year ending december portfolios sustainability core website contains information business practices award reflects permanent nature well latest roche news commitment running business way companys articles incorporation bylaws ethical responsible creates longterm value curricula vitae current former status stakeholders per end term reporting date december year least last five corporate governance report sets years members board directors structures processes rules roche corporate executive committee published takes basis wellfunctioning corporate website material topic compliance httpswwwrochecomaboutgovernancehtmcorporate governance roche annual general meeting annual general meeting board directors board directors board committees board committees chairmansnomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceuticals diagnostics information officer officer enlarged corporate executive enlarged corporate executive committee committee gred pred partnering communications general counsel board directors accordance art federal act structure composition remaining statutory principles federal council committees shown see also ordinances combating covid epidemic board directors covid act art ordinance corporate executive committee measures combat coronavirus covid covid ordinance rd annual general march forthcoming agm meeting agm roche holding ltd held board directors nominates chairman march without physical participation remaining members board directors shareholders shareholders requested reelection exception mr paul bulcke exercise rights via independent proxy prof dr hans clevers paul bulcke testaris ag address questions serving board directors since company writing decided stand reelection agm following almost eleven years agm roche holding ltd march tenure prof dr hans clevers joined shareholders reelected dr christoph franz board directors step chairman board directors term one position appointed new head year provided articles incorporation roche pred effective march become member enlarged corporate furthermore agm reelected andr hoffmann executive committee board directors julie brown paul bulcke prof dr hans clevers proposes dr jemilah mahmood currently dr jrg duschmal dr patrick frost anita hauser special advisor public health malaysias prof dr richard p lifton bernard poussot prime minister election board dr severin schwan dr claudia suessmuth directors agm dyckerhoff members board directors term one year provided articles moreover board directors nominates incorporation dr christoph franz andr hoffmann prof dr richard p lifton bernard poussot addition addition agm elected dr christoph franz dr patrick frost election remuneration andr hoffmann prof dr richard p lifton committee agm bernard poussot members remuneration committee term one year board directors nominates testaris ag election independent proxy agm organising meeting immediately following period conclusion agm board directors determined ordinary agm shareholders board directors board directors board committees board committees chairmansnomination committee remuneration committee audit committee corporate governance sustainability committeecorporate governance roche board directors members nationality france belgium uk female netherlands switzerland male austria us germany years years years years years years years age tenure average tenure incl ceo years excl ceo incl dual citizen triple citizen calculated year first election composition name year birth first elected board directors dr christoph franz c e g chairman andr hoffmann c e g vicechairman representative shareholder group pooled voting rights dr jrg duschmal b e g representative shareholder group pooled voting rights julie brown b e g paul bulcke b e g prof dr hans clevers e g dr patrick frost b e g anita hauser e g prof dr richard p lifton c e g bernard poussot c e g dr severin schwan f dr claudia suessmuth dyckerhoff e g secretary dr annette luther board directors curricula vitae cvs members board directors current members httpswwwrochecomaboutgovernanceboardofdirectorshtm b former members least last five years httpswwwrochecomaboutgovernanceecbodformerhtm c nformation cvs reporting date december year least last five years httpswwwrochecomaboutgovernancearchivformercvshtm corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson board directors b c committees andr hoffmann chair julie brown chair andr hoffmann chair dr christoph franz chair prof dr hans clevers dr jrg duschmal dr christoph franz andr hoffmann anita hauser paul bulcke prof dr richard p lifton dr claudia suessmuth dyckerhoff dr patrick frost bernard poussotcorporate governance roche corporate executive committee memberships corporate executive corporate executive committee listed committee remained unchanged see also board directors corporate executive committee information member corporate executive committee enlarged corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceuticals diagnostics information officer officer enlarged corporate executive enlarged corporate executive committee committee gred pred partnering communications general counsel composition name year birth position since corporate executive committee dr severin schwan ceo roche group bill anderson ceo roche pharmaceuticals dr thomas schinecker ceo roche diagnostics dr alan hippe chief financial information officer cristina wilbur chief people officer enlarged corporate dr aviv regev head genentech research executive committee early development gred dr william pao head roche pharma research early development pred dr james h sabry global head pharma partnering barbara schdler head group communications claudia bckstiegel general counsel secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge j ohn morris ian starkey mark baillache business year chief compliance officer pascale schmidt curricula vitae cvs members corporate executive committee enlarged corporate executive committee current members httpswwwrochecomaboutgovernanceexecutivecommitteehtm b former members least five years back httpswwwrochecomaboutgovernanceecbodformerhtm c information cvs reporting date december year least last five years httpswwwrochecomaboutgovernancearchivformercvshtm group structure shareholders roches operating businesses organised business activities carried group two divisions pharmaceuticals diagnostics subsidiaries associated companies detailed information roche holding ltd significant pharmaceuticals division comprises subsidiaries associated companies including two business segments roche pharmaceuticals company name listing information domicile share chugai whereas genentech former capital equity interest listed finance third segment integrated roche report note roche group consolidated pharmaceuticals financial statements list subsidiaries associates part transformation initiative diagnostics division replaced previous major shareholders listed finance business area structure four business areas report notes roche group centralised point care solutions molecular consolidated financial statements equity diagnostics tissue diagnostics diabetes care attributable roche shareholders related new customer areas sales presented parties pages note following customer areas core lab molecular financial statements roche holding ltd lab point care diabetes care pathology lab significant shareholders addition details see finance report significant shareholders published roche pharmaceuticals incl genentech pharmaceuticals chugai business areas customer areas centralised point care solutions core lab diagnostics molecular lab molecular diagnostics point care tissue diagnostics pathology lab diabetes care diabetes care composition corporate governance roche relevant webpage see link disclosure office six exchange regulation andr hoffmann vicechairman board directors chairman remuneration committee boards corporate governance sustainability committee member boards chairmansnomination committee dr jrg duschmal member board directors boards audit committee serve respective capacities board committees representatives shareholder group pooled voting rights receive remuneration set forth remuneration report finance report note roche group consolidated financial statements related parties relationships exist shareholders pooled voting rights crossshareholdings andr hoffmann chairman corporate governance sustainability committee remuneration committee dr jrg duschmal member audit committee six exchange regulation httpswwwseragcomenresourcesnotificationsmarketparticipantssignificantshareholdershtml capital structure information roches capital structure provided earnings liquidation proceeds following finance report notes financial repayment share capital roches nes statements roche holding ltd rights pertaining thereto including additional details contained articles provisions protecting interests nes holders incorporation roche holding ltd described articles incorporation roche holding ltd movement recognised amounts last three financial years detailed finance information debt instruments report notes financial statements issued outstanding bonds roche holding ltd provided finance report note roche group consolidated financial statements extraordinary general meeting held debt november shareholders agreed reduce companys share capital information employee stock options provided chf amount chf finance report note roche chf cancellation group consolidated financial statements equity bearer shares nominal value compensation plans including detailed chf repurchased information stocksettled stock appreciation company novartis holding ag pursuant rights ssars plan restricted stock units repurchase agreement dated november rsus plan roche connect roche difference acquisition cost option plan nominal value bearer shares cancelled accounted reduction roche issued options apart employee voluntary reserves retained earnings stock options described finance report note roche group consolidated financial authorised conditional capital statements equity compensation plans options issued connection debt addition nonvoting equity instruments securities nes issued bearer form form part share capital neither options awarded employees confer voting rights nes confers debt instruments issued rights one share participate available effect roches share capital httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche board directors corporate executive committee information member board directors independence definition based directors member corporate definition swiss code best practice executive committee listed pages corporate governance economiesuisse members board directors age limit complemented specific preceding criteria restriction term office see httpswwwrochecomaboutgovernance boardofdirectorshtm curricula vitae cvs current former members least last five years principles governance principles bodies information including information delegation competence reservation powers years first election additional management group companies positions memberships activities available executive bodies company include continuously updated internet economic environmental social topics addition status cvs bodies principles together internal organisation relevant reporting date december least board directors division authority last five years separately available responsibilities board management remits board committees rules pursuant article para point vegv information control mechanisms number permitted activities board available board dealings corporate directors corporate executive committee management governed bylaws members outlined articles incorporation roche holding ltd board directors roche holding ltd organised ensure group conducts since annual general meeting elected businesses responsibly focus members board directors chairman longterm value creation end roche board directors members board delegated certain responsibilities remuneration committee annual basis several committees composition elections nominee voted chairpersons december described separately see articles incorporation pages committees authorities roche holding ltd minutes responsibilities defined detail rd annual general meeting roche holding ltd bylaws board directors held march committees chaired independent exception dr severin schwan none directors members board directors office end member roches according bylaws board directors corporate executive committee served board meeting may convened without executive capacity group subsidiary chairman present request five financial years preceding current members roche board meets year reporting period lack existing assess chairmans performance meeting business connections group attended chairman chaired group subsidiary independent roches board vicechairman httpswwwrochecomaboutgovernanceboardofdirectorshtm httpswwwrochecomaboutgovernanceexecutivecommitteehtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernanceannualgeneralmeetingshtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancecommitteeshtm httpswwwrochecomaboutgovernancearticleofincorporationhtm board directors board directors board committees board committees chairmansnomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceuticals diagnostics information officer officer part management information system risk plans material risks mis board directors regularly monitored deviations reviewed regular informed important issues sales performance dialogues consolidated performance etc board access group risk report including target risk profile electronic information platform provides discussed corporate executive committee timely information board directors approved together group business board committees system plan material risks reviewed board controls set forth yearly basis effectiveness risk management process monitored group board directors established system risk advisory team overall process controls continuously monitored regularly reviewed external auditors audit committee corporate governance findings presented audit committee sustainability committee board full board details risk management directors consists following elements including risk factors risk management report operating financial risks risk policy see risk management website management system financial risk management specifically described roche group established risk finance report management process covering entire system internal controls financial reporting company system place identify see finance report manage types risks potentially affecting internal audit business including economic environmental group audit reports general counsel social impacts risks opportunities direct access gives regular briefings stakeholder input board directors audit committee corporate highest governance body involved roches governance sustainability committee risk management policy sets approach ongoing activities audit reports chief accompanying responsibilities audit risk advisory executive attends audit pharmaceuticals diagnostics divisions committee partly corporate governance global functions conduct formal risk assessment sustainability committee meetings process least year must develop external auditors group audit independent httpswwwrochecomsustainabilityapproachriskmanagementhtm additional information provided finance report note roche group consolidated financial statements risk management corporate governance roche appraisal function evaluates reviews following blackout periods arewere effect groups activities service board respectively directors management annual audit plan yearly defined focus areas eg market blackout periods access thirdparty management validated senior management approved audit december december committee roche group committed february february maintaining high standard internal control april april april april throughout worldwide operations management june july june july responsible assessing business risks october october aspects operation implementing october october effective efficient processes controls whilst ensuring compliance internal external rules regulations conducting blackout periods changed chairman operational audits group audit determines board directors circumstances warrant managements response risks surrounding business processes systems evaluates roche employees involved preparation appropriateness completeness efficiency regular publicity events particular annual processes controls action plans halfyear reports media conferences quarterly implement necessary changes enhancements sales releases otherwise access developed together businessauditee potentially share price sensitive information tracked completion roche roche employees resident statutory auditors see us including us citizens green card chief compliance officer compliance holders resident aliens well terminated officers subsidiaries see employees retirees fall one safety health environmental protection us categories subject blackout department periods irrespective whether relevant corporate sustainability committee information share price sensitive roche science ethics advisory group seag blackout periods persons issues relating genetic engineering shall keep relevant information confidential must disclose noninsider within members corporate executive outside roche including family members ii committee invited attend meetings buy sell otherwise trade equity securities board directors report person roche shares nonvoting equity securities agenda items concerning nes well options similar instruments situation warrants members enlarged derivatives based thereon iii provide trading corporate executive committee may also recommendations thereon automatic execution invited attend board committees invite predefined periodic purchase orders chairman board corporate executive roche connect programme subject committee members deliver reports blackout periods committee meetings may elect commission independent expert reports call services addressees scope exceptions regard consultants blackout periods please refer roche group insider directive httpswwwrochecom year several blackout periods imposed damjcrdfbdadccadaacabeb members board directors engroupinsiderpolicypdf senior certain employees prohibited trading company stock httpswwwrochecomsustainabilityenvironmenthtm httpswwwrochecomsustainabilityhtm httpswwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm julie brown chairwoman audit committee board directors met meetings ordinary meetings hours length including fullday meeting extraordinary board meetings hours length held connection major business transactions addition board went day trip european affiliate board committees met follows chairmansnomination committee meetings approx hours remuneration committee meetings approx hours audit committee meetings approx hours corporate governance sustainability committee meetings approx hours board directors regularly conducts assessment selfassessment assessment third parties via electronic survey personal interviews performance members corporate executive committee maximum ordinary notice period twelve months changeofcontrol clauses employment contracts management contracts fall within scope subsection annex six directive information relating corporate governance remuneration committee members recuse deliberations decisions matters affect interests figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activitiescorporate governance roche attendance board board committee meetings corporate chairmans governance nomination remuneration audit sustainability board committee committee committee committee number meetings c franz hoffmann j duschmal j brown p bulcke h clevers p frost hauser rp lifton b poussot schwan c suessmuth dyckerhoff member committee remuneration shareholdings loans details regarding remuneration shareholdings rules aoi loans content method determining content board cec compensation shareholding programmes rules principles basic principles elements compensation applicable performance shareholding programmes serving former related pay members board directors corporate rules principles executive committee together description allocation equity securities authorities procedure determining convertible rights options set forth separate remuneration report additional amount pages finance report payments members notes roche group consolidated executive committee financial statements equity attributable roche appointed vote shareholders related parties pages pay annual general listed note financial meeting shareholders statements roche holding ltd board rules loans credit facilities executive shareholdings postemployment benefits rules vote pay following rules remuneration shareholdings agm loans board directors board corporate executive committee cec set forth articles incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche participatory rights shareholders participatory rights shareholders articles incorporation defined roches articles incorporation shareholders representing shares nominal roche shares issued bearer value least chf million request restrictions admission annual general placement items agenda annual meetings exception shares must general meeting must done later deposited within specified period days date meeting date meeting admittance card must issued shareholders name provided rules issue instructions articles incorporation shareholder independent proxy rules electronic elect represented third party participation annual general meeting annual general meeting laid corresponding invitation annual general meeting regulated articles incorporation contain restrictions articles incorporation exercise voting rights quorum requirements stipulated conformity swiss code obligations change control defensive measures articles incorporation contain provisions nonvoting equity securities would terminated mandatory bid rule swiss law applies event acquisition vesting period restrictions preexisting awards would changeofcontrol clauses removed options could components remuneration based roche exercised immediately httpswwwrochecomaboutgovernancearticleofincorporationhtm relationship statutory auditors annual general meeting roche holding ltd potential nonaudit service engagement march shareholders voted reviewed policy authority appoint kpmg ag kpmg statutory auditors proceed given based existing legal requirements auditors direct access audit swiss code obligations article concerning committee chair well head maximum term office seven years group audit discuss relevant issues auditor charge mark baillache auditor charge since business year reports statutory auditor information long auditor charge consolidated financial statements serving capacity provided financial statements found pages statutory auditors participate respectively finance report audit committee meetings prepare written oral reports results audits kpmg received following remuneration audit committee oversees assesses services statutory auditors roche holding ltd auditors makes recommendations auditors roche companies board information authorities including chugai responsibilities audit committee see article bylaws statutory auditors participated six meetings audit millions chf committee auditing services auditrelated services performance kpmg assessed based assurance different elements affiliate surveys nonstatutory audits evaluate service level country level tax services interviews roche key stakeholders services selfevaluation kpmg internal processes total ensure compliance federal audit oversight authority faoa audit committee guide audit fee reviewed head group audit kpmgs independence ensured limiting approved audit committee every year kpmg providing certain nonaudit services takes consideration changes roches furthermore permitted services exceed business well changes financial reporting total audit fee unless explicitly audit standards regulations rewieved approved audit committee company formal policy governing statutory auditors elected year engagement statutory auditor nonaudit annual general meeting services limits certain permitted services agreed audit committee auditing services provided legally required httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche auditrelated services include assurance tax services include services respect accounting services provided auditors compliance tax returns tax advice except necessarily provided statutory services related audit tax auditor services go beyond legal requirements could include attestation services include advice relating process services comfort letters consultations improvements regulations trainings relationship independent proxy since testaris ag served board directors nominates testaris ag independent proxy annual general election independent proxy annual general meeting march shareholders meeting period elected testaris ag independent proxy conclusion ordinary annual general period conclusion meeting shareholders ordinary annual general meeting shareholders testaris ag paid rules issue instructions independent services annual general meeting proxy rules electronic participation extraordinary geneneral meeting annual general meeting laid november according expenditure totalling corresponding invitation annual general meeting chf chf regulated articles incorporation information policy provided articles incorporation presentations analyst investor conferences corporate notices published swiss available internet publications official gazette commerce daily available newspapers designated board directors httpswwwrochecompublicationshtm basler zeitung finanz und wirtschaft lagefi ordered email le temps neue zrcher zeitung baselwarehouseservicesrochecom fax roche reports halfyear fullyear results business reports published print andor online contact address investor relations formats media events addition detailed f hoffmannla roche ltd investor relations firstquarter nine months sales figures group finance basel switzerland published year april october tel current list publication dates available fax internet additional information including details relevant information documents including specific contact persons available media releases investor updates internet httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecommediahtm httpswwwrochecominvestorshtm httpswwwrochecominvestorscontactshtmcorporate governance roche chief compliance officer compliance officers network chief compliance officer compliance line compliance tool furthermore serves officers network committed ensuring platform ideas suggestions concerning roche group code conduct consistently documents complied throughout roche group chief compliance officer also serves contact addition roche established business ethics person shareholders employees business incident reporting beir system enables partners customers suppliers general chief compliance officer capture track public issues relating implementation monitor alleged violations initial reports compliance code local compliance officers group internal investigations department resolution employees parties become aware violations roche group code conduct business ethics incidents recorded bring attention managers system group internal investigations supervisors local compliance officer department regionallocal management report chief compliance officer receives specific concrete information ms pascale schmidt alleged violation roche group code email pascaleschmidtrochecom conduct one certain predefined categories tel disclosures corporate governance sustainability treated confidentially addition employees may committee audit committee board anonymously report irregularities complaints directors informed substantial violations mother tongue via speakup line case managements corrective actions taken questions uncertainties interpretation roche group code conduct chief compliance officer reports reference documents employees may reach general counsel also submits regular reports line managers local compliance officer corporate governance sustainability chief compliance officer contact committee needed audit committee roche group code conduct help advice board directors nonapplicabilitynegative disclosure expressly noted information negative declaration provided six swiss contained mentioned herein either non exchange corporate governance directive applicable omission construed commentary thereto httpswwwrochecomaboutgovernancecodeofconducthtm httpswwwrochecomaboutgovernancecodeofconductcomplianceofficerhtm httpswwwrochecomaboutgovernancecodeofconducthtmremuneration report roche remuneration report principles roche innovative agile company whose along performance successbased success depends substantially expertise transparent compensation structure ensure motivation performance employees compensation packages competitive conviction forms basis compensation structure individual components policy regularly benchmarked based relevant swiss european international market criteria roche aims remunerate employees fairly remuneration guidelines underlying transparently line market conditions principles also subject regular outside enable participate appropriately comparisons companys success pursue goal providing equitable competitive performance however compensation policy one factor based resultsoriented compensation safeguarding roches future success key element corporate culture offers strive balanced mix fixed variable employees conditions make compensation components geared best possible contribution shared corporate employees position management responsibility goal improving healthcare patients includes sound sustainabilityoriented firstly variable components intended value system based integrity courage create additional financial incentives achieve passion time decentralised corporate goals keep innovation management approach plays major role consistently high level increasing value wide scope individual decisionmaking company creates stakeholder respectful interactions openness diversity wide groups secondly order allow employees ranging training development opportunities managers participate companys business attractive working environment unidimensional success adequate compensation measures diminishment questions remuneration would key objectives incentivised annual fall far short bonus payments longterm securitiesbased programmes roche committed fair performancebased resultsoriented compensation policy links global company like roche market employees interests various competitive remuneration plays key role stakeholder groups compensation policy httpswwwrochecomcareersforemployeesrewardshtm sound value system httpswwwrochecomcareersforemployeeslivingourvalueshtmremuneration report roche remuneration decision process approval framework overview must present remuneration year remuneration committee roches committee decides corresponding board directors decides remuneration compensation right say decisions board members members groups decision right reserved remuneration corporate executive committee committee members chairman group ceo members groups corporate executive committee remuneration decision process approval framework beneficiary remuneration board directors bod corporate executive decision approval components chairman c committee cec incl ceo roche group base pay remuneration bonus c stocksettled stock remuneration committee annual general meeting appreciation rights ssars restricted stock units rsus pension c remuneration committee tracks market data since total aggregate amounts salaries leading global pharmaceutical based decisions submitted companies major swiss companies general meeting approval implementing reports findings full board external ordinance excessive compensation consulting firm pricewaterhousecoopers pwc listed jointstock companies verordnung gegen assists remuneration committee roche bermssige vergtungen bei brsenkotierten performing market comparisons advising aktiengesellschaften vegv general meeting pwc awarded additional mandates shall vote annually binding effect roche group information remuneration approval remuneration board committees remit powers procedures directors resolved board directors making remuneration decisions found corporate executive committee details bylaws roche board directors see articles incorporation also outlined sections principles governing specific remuneration components see peer set abbott laboratories abbvie amgen astrazeneca bristolmyers squibb danaher eli lilly glaxosmithkline johnson johnson medtronic merck co novartis novo nordisk pfizer sanofi abb alcon credit suisse holcim lonza nestl richemont ubs zurich httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancearticleofincorporationhtm abbott laboratories abbvie amgen peer set astrazeneca bristolmyers squibb abb danaher alcon eli lilly credit suisse glaxosmithkline holcim johnson johnson lonza medtronic nestl roche merck co richemont novartis ubs novo nordisk zurich pfizer sanofi peer set market comparison companies salary assessment pharma peer set major swiss companies procedure submitting total board retrospective approval executive remuneration shareholder total aggregate bonus amounts corporate approval annual general meeting executive committee chairman year annual general meeting agm board directors financial year ended shareholders approve total remuneration submitted retrospectively ordinary board directors corporate agm separate binding approval executive committee decided board directors remuneration committee prospective approval board directors respectively board executive aggregate remuneration submitted prospectively according approval agm agm separate binding approval roche committed obtaining separate period two ordinary agms binding shareholder approvals total remuneration paid board directors corporate executive committee followsremuneration report roche andr hoffmann chairman remuneration committee approval total remuneration annual general meeting agm financial year financial year retrospective c bonus chairman c board directors bod bonus financial year total amount cec corporate executive committee cec including ceo roche group bonus bonus financial year total amount prospective bod base pay remuneration board directors bod including chairman c aggregate total remuneration agm agm base pay remuneration cec corporate executive committee cec including ceo roche group base pay aggregate total remuneration agm agm ssars base pay rsus stocksettled stock appreciation rights ssars indirect benefits restricted stock units rsus indirect benefits agm agm agm remuneration components overview remuneration elements performance nonfinancial success thus remuneration members board align interests roche employees directors corporate executive committee shareholders societal environmental composed following elements objectives also taken account fixed base salary complemented lti remuneration components intended annual variable bonus shortterm incentive sustainably homogenously longterm sti perennial remuneration elements oriented perspective align managements interest ssars rsus longterm incentive lti shareholders holders non voting equity securities give participating remuneration components linked managers additional incentive achieve employees performance companys financial sustainable shareholder value growth composition remuneration board directors corporate executive committee board directors corporate executive committee annual remuneration elements description c bod ceo roche group cec base pay monthly payment quarterly remuneration see payments bonus annual payment years years cash see blocked nonvoting blocked nonvoting equity securities equity securities andor shares andor shares pensions etc see perennial remuneration elements stocksettled stock see years appreciation rights additionally ssars blocked nonvoting equity securities exercise restricted stock see years units rsus blocked nonvoting equity securities httpswwwrochecominvestorssustainabilitydownloadcenterperformancehtm httpswwwrochecomsustainabilityenvironmentourshegoalsandperformancehtmremuneration report roche lti corporate executive committee expiration periods aligned newly enlarged corporate executive issued ssars rsus see unlike committee composed ssars participants two programmes members rsus based already existing individual corporate executive committee target value total lti corporate executive choice determining mix rsus ssars committee members base pay fouryear cliff vesting measured january year vesting corporate executive committee lti mix ssarsrsus fixed base calculation vesting period cliff vesting expiration period based individual target ssars value total lti years years years corporate executive committee members base pay rsus measured january years years year remaining participants ssars offering level choice empowers participants rsus programmes offered yearly basis engage fully total rewards enables choice three combinations determine mix better understand critical element restricted stock units rsus stocksettled compensation increases value stock appreciation rights ssars options used programme instead ssars countries following options available attractively designed roche longterm incentive programme enables roche attract choice choice choice motivate retain best talent keep ssars ssars ssars aligned companys longterm success rsus rsus rsus fixed base salary indirect benefits employer contribution pensions insurance contributions roche roche connect sti remuneration tax consulting services bonus components expense allowances lti stocksettled stock appreciation rights others restricted stock units childrens schooling costs foreign tax obligation variable longterm ahvivalv employer contribution social securities beneficial parts base pay fixed bonuses variable base pay cash payment determined bonuses annually awarded individual position based salary market data contributions value creation business year leading global pharmaceutical companies see meant incentive strive outstanding footnote major swiss companies results create new business opportunities see footnote reflects individuals abilities bonus amounts linked group divisional experience performance time pay core profits sales growth constant exchange adjustments likewise linked individual rates operating profit capital charge opac performance take account prevailing based core operating profit core earnings per market conditions companys overall share nonvoting equity security nes growth financial situation constant exchange rates product development pipeline diversity employees managers remuneration committee makes reviews environmental goals additionally linked final decision individual base pay paid achievement measurable qualitative chairman board directors individual functional performance objectives members corporate executive committee competitive reasons roche disclose remuneration members individual performance objectives members board corporate executive committee chairman httpswwwrochecomcareersforemployeesdiversityhtm httpswwwrochecomsustainabilityenvironmentourshegoalsandperformancehtm goals roche group httpswwwrochecomdamjcrbcfadadaffeedenshegoalscommunicationpdfremuneration report roche december end reporting year restricted stock units rsus longterm january following reporting year proportion restricted stock units rsus remuneration committee decides bonuses members corporate executive committee amounts payable chairman total lti based individual board members corporate executive target value total lti corporate executive committee respect relevant reporting year committee members base pay based performance aforementioned measured january year objectives time remuneration committee also decides form bonuses rsus contain rights receive nonvoting equity awarded ie cash payments andor blocked securities andor shares fouryear vesting applicable nonvoting equity securities andor period plus value adjustment amount shares equivalent sum dividend paid vesting period attributable number remuneration committee uses discretion nonvoting equity securities andor shares appropriately weighting criteria individual award granted bonus allocation vested recipient corporate executive committee four years total around employees thereafter resulting nonvoting equity eligible bonus roche bonus program securities andor shares may remain blocked ten years stocksettled stock appreciation rights ssars longterm rsu awards allocated individually ssars proportion lti corporate corporate executive committee executive committee based remuneration committees discretion individual target value total lti corporate executive committee members rsus served remuneration component base pay measured january year eligible roche employees ssars entitle holders benefit financially indirect benefits increase value roches nonvoting shown ceo roche group equity securities grant date chairman respectively members exercise date ssars granted vest together corporate executive committee additionally four years exercised received indirect benefits pension funds insurance within ten years grant date unexercised contributions roche connect payments foreign ssars lapse without compensation since tax obligation tax consulting services fair value ssars calculated annual expense allowances shown grant date using trinomial model american individual members corporate executive call options details see committee received payments family children education allowances schooling costs ssars corporate executive committee children allocated individually remuneration committees discretion total employees received ssars weighting fixed variable longterm remuneration components target percentage total remuneration chairman board directors corporate executive committee including ceo roche group fixed variable longterm variable longterm remuneration paid members corporate executive committee ranged total compensation ratio variable remuneration components relative fixed base pay corporate executive committee ratio variable remuneration components bonuses ssars rsus relative value fixed base pay lti longterm sti variable total criteria bonus ssars total lti rsus total lti individual target value minimum maximum performance criteria group objectives group divisional business value development value development performance individual objectives considering determined determined core profits sales growth constant exchange rates performance performance plus operating profit capital charge opac based nes grant value adjustment core operating profit core earnings per share dividends nonvoting equity security nes growth constant nes grant exchange rates product development pipeline diversity employees managers environmental goals split group objectives na na b individual objectives na na weighting criteria remuneration committees discretion decision objectives na applicable assessed consideration performance competitors macroeconomic development based already existing individual target value total lti corporate executive committee members base pay measured january year details please refer following sections remuneration report see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings remuneration board directors resolution approval board directors table remuneration chairman board board activities roche paid employers directors members board directors contributions totalling chf social decided remuneration committees security agencies members board discretion taking account market comparisons directors beside legally required contributions separately stated chairman board remuneration form cash payments directors annually tracked market data directors pay leading global pharmaceutical basic remuneration board directors companies see footnote major swiss excluding chairman remained unchanged companies see footnote assisted since consultancy pwc exception chairman board previous years board directors bonus form blocked shares directors separately submit total aggregate dr severin schwan executive member bonus chairman board directors board members board directors general meeting financial year awarded shares nonvoting equity retrospective binding approval securities ssars maximum amounts total aggregate loans credits granted remuneration board directors members board directors period ordinary general meeting ordinary general meeting capacity member chugai separately tabled previous international council cic chugai years general meetings prospective binding pharmaceutical co ltd andr hoffmann approval see received honoraria amounting total usd chf amount remuneration members board directors advisory service members board directors genentech scientific resource board received remuneration additional compensation prof dr richard p lifton prof dr hans clevers form quarterly fixed cash payments received honoraria amounting total shown remuneration members usd chf list members positions committee memberships chairmanships see detidua remuneration report roche remuneration members board directors chf additional remuneration additional special additional basic remuneration committee memberschairs remuneration bvg costs total remuneration c franz chairman see total remuneration paid chairman board directors hoffmann vicechairman see j brown p bulcke h clevers see j duschmal p frost hauser rp lifton see b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff total costs provisions swiss federal occupational old age survivors invalidity pension act bvg accordance minimum requirements insurance benefits bvg half costs four members board directors subject compulsory insurance borne company exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration detidua remuneration members board directors chf additional remuneration additional special basic remuneration committee memberschairs remuneration total remuneration c franz chairman see total remuneration paid chairman board directors hoffmann vicechairman j brown p bulcke h clevers j duschmal since march p frost since march hauser rp lifton b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff j bell march oeri march total exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december prorated remuneration period january march additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration total remuneration paid chairman ten years payable march put board directors shareholder binding vote ordinary chairman dr christoph franz received total annual general meeting agm remuneration shown remuneration committees bonus proposal chairmans total remuneration contained adopted late respect total remuneration board directors financial year form shares blocked detidua remuneration report roche total remuneration paid board addition sir john bell social security directors contributions amounting chf calendar year members paid foreign state social security institution board directors received remuneration including bonuses employer contribution additional remuneration paid social securities beneficial parts totalling chf chf excluding board remuneration subject approval additional employers contribution paid annual general meeting social securities totalling chf chf includes contributions submission chairmans total foreign authorities amounting chf aggregate bonus binding vote annual general meeting remuneration paid former members remuneration chairman board board directors directors includes bonus award chf former member board directors dr franz form shares blocked ten years shown b humer received fees amounting table section total remuneration paid total usd chf serving chairman board directors board member chugai international council cic directors submit remuneration committees chugai pharmaceutical co ltd former member bonus proposal adopted late board directors william burns chairman board dr christoph franz respect received fees amounting total usd financial year payable march chf capacity member excluding legally required employers contributions chugai international council cic chugai ahvivalv shareholder binding vote pharmaceutical co ltd ordinary annual general meeting detidua detidua total remuneration paid chairman board directors chf base salary cash tax equalisation pension fund corrections na na bonus subject approval annual general meeting pension funds insurances annual expense allowances tax social security including employer contribution social securities beneficial parts total na applicable form shares blocked years calculation number shares based price date transfer march respectively approval agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm respectively agreed reduction pension fund contributions upon reaching age dditionally employer contribution ahvivalv chf chf paid form part remuneration detidua remuneration report roche retrospective approvals chairmans total aggregate bonus chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv bonus award form shares blocked years calculation number shares based price date transfer march march march respectively approval agm agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm agm respectively submission boards total aggregate dr severin schwans remuneration shown future remuneration binding shareholder receives function ceo vote roche group member corporate board directors proposes executive committee included ordinary agm approve board remuneration totalling part corporate executive committees chf excluding legally total remuneration required employers contributions ahvivalv excluding bonuses period ending ordinary agm prospective approvals boards total aggregate future remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported excluding bonuses period ending remuneration shareholders ordinary agm approved remuneration members board directors comparison ordinary agm ordinary agm approved board ordinary agm actual remuneration remuneration totalling amounted chf excluding legally chf excluding legally required required employers contributions ahvivalv employers contributions ahvivalv excluding bonuses prospectively approved total remuneration members board directors comparison actual total payments made chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approved agm actual total remuneration paid calculation end period within approved limit calculation end period yes yes excluding legally required employers contributions ahvivalv excluding bonuses security holdings statements related parties directors andr hoffmann dr jrg duschmal note financial statements members founders families roche holding ltd significant shareholders closely associated belong addition december contractually bound shareholder group december respectively pooled voting rights end members board directors persons group held shares issued closely associated held roche shares shares detailed information group nonvoting equity securities nes american found finance report note depositary receipts adrs shown roche group consolidated financial table security holdings security holdings shares nes december december nonvoting nonvoting close equity close relatives equity relatives securities security others securities security others shares nes holdings number shares nes holdings number number number numbertype type number number numbertype type board directors c franz hoffmann j brown p bulcke h clevers j duschmal p frost hauser nes nes rp lifton adrs adrs b poussot schwan see security holdings see security holdings corporate executive committee corporate executive committee c suessmuth dyckerhoff total nes adrs nes adrs shares held shareholder group pooled voting rights listed jointly held close relative roches adr american depositary receipt listed otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin us traded usd eight adrs represent one underlying nesremuneration report roche remuneration corporate executive committee resolution approval amount remuneration members remuneration members corporate corporate executive committee executive committee decided general provisions assigning authority remuneration committees discretion taking decisions corporate executive committee account market comparisons remuneration remuneration committee board directors outlined previous years board remuneration decision process approval directors separately submit total aggregate framework bonuses corporate executive committee general meeting financial year members corporate executive retrospective binding approval committee received remuneration work shown amount remuneration maximum amounts total ceo roche group dr severin schwan aggregate remuneration corporate explained detail executive committee period ordinary general meeting ordinary general meeting tabled previous years general meetings prospective binding approval see highest total remuneration paid highest total remuneration paid member dr severin schwan member corporate executive committee see corporate executive committee included total amount paid corporate dr severin schwan executive member board executive committee see total remuneration directors received remuneration primary paid members corporate executive function ceo roche group reflected committee highest total remuneration paid dr severin schwan member corporate executive committee chf base salary bonus subject approval total aggregate bonuses corporate executive committee annual general meeting ssars rsus roche connect pension funds insurances payments incl expense allowance tax consulting services total detailed calculation remuneration see annual report light overall economic impact covid pandemic dr severin schwan waived amount chf contractual base salary shares blocked years calculation number shares based share price date transfer march approval agm sars number grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee ssars blocked years may thereafter exercised whilst exercising resulting nes automatically blocked additional years calculation value nonvoting equity securities consideration reduction value due additional blocking period years reduced market value ssars number grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee ssars blocked years may thereafter exercised whilst exercising resulting nes automatically blocked additional years calculation value nonvoting equity securities consideration reduction value due additional blocking period years reduced market value calculation rsus value number rsus multiplied grant value chf nes closing price grant date march per rsu calculation rsus value number rsus multiplied grant value chf nes closing price grant date march per rsu includes annual expense allowance chf payments tax consulting services chf chf family children education allowance chf chf additionally employer contribution ahvivalv chf chf paid form part remuneration calculation value nonvoting equity securities shares consideration reduction value due blocking period years reduced market value including employer contribution social securities beneficial parts detidua base pay members corporate executive committee base pay chf b anderson hippe schinecker c wilbur total bonuses members bonuses brought forward binding corporate executive committee vote annual general meeting remuneration committee board directors determined corporate executive except dr severin schwan members committee members bonuses based corporate executive committee receive performance agreed objectives bonus cash payment dr severin remuneration committee uses discretion schwan receive bonus form roche appropriately weighting criteria shares blocked ten years see bonus allocation total aggregate amount bonus payment due march bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting b anderson hippe schinecker c wilbur total detidua detidua remuneration report roche stocksettled stock appreciation based already existing individual target rights ssars members value total lti corporate executive corporate executive committee committee members base pay ssars corporate executive committee measured january year allocated individually remuneration committees discretion ssars shown fair value ssars calculated ssars table entitle holders grant date using trinomial model american benefit financially increase value call options trinomial model effective roches nonvoting equity securities nes method valuation american call options grant date exercise date strike considers possibility exercising option price ssars terms multiyear time prior maturity called american option plan closing price roche nes grant compared european option date ssars since vest four previously allows exercise maturity date granted ssars three years grant date vested ssars exercised converted numbers ssars strike prices expiry nes within ten previously granted ssars within dates grant values ssars shown seven years grant date unexercised ssars ssars table lapse without compensation numbers ssars calculated time issue entered values table since ssars proportion lti corporate executive committee restricted stock units rsus rsus contain rights receive nonvoting equity members corporate securities andor shares since newly executive committee defined fouryear vesting period plus value since proportion restricted stock units adjustment amount equivalent rsus members corporate executive sum dividend paid vesting period committee total lti based attributable number nonvoting equity already existing individual target value total securities andor shares individual lti corporate executive committee members award granted vested base pay measured january recipient corporate executive committee year rsu awards allocated individually four years thereafter resulting non corporate executive committee voting equity securities andor shares may remain remuneration committees discretion blocked ten years information trinomial model american call options please refer boyle phelim p lattice framework option pricing two state variables journal financial quantitative analysis volume issue mar httpswwwrochecomdamjcraaacbfa bcbeacentrinomialmodelpdf detidua stocksettled stock appreciation rights ssars grant value per grant value per number ssar chf value chf number ssar chf value chf b anderson hippe schinecker c wilbur total price chf expiry date price chf expiry date detidua restricted stock units rsus value grant value grant number chf value chf number chf value chf b anderson hippe schinecker c wilbur total calculation value consideration reduction value due additional blocking period years reduced market value calculation value consideration reduction value due additional blocking period years reduced market value indirect benefits members roche nonvoting equity securities nes corporate executive committee amount equal annual salary employer contributions made social discount nes purchased plan security schemes pension plans groupwide subject holding period four years employee stock purchase plan roche connect switzerland respect members corporate executive committee shown indirect benefits addition members corporate executive employer contributions table committee received annual expense allowances table members payments foreign tax obligations tax consulting services shown roche connect voluntary stock purchase table plan offering employees opportunity buy detidua remuneration report roche indirect benefits employer contributions chf payments payments annual tax tax annual tax tax pension funds expense roche consulting pension funds expense roche consulting insurances allowances connect services insurances allowances connect services b anderson hippe schinecker c wilbur total including employer contribution social securities beneficial partsdetidua detidua detidua remuneration loans members contribution social securities beneficial parts corporate executive committee totalling chf chf excl ceo roche group excluding additional employers contribution meet legal contractual obligations paid ahvivalv totalling chf roche paid total chf individual chf form part members corporate executive committee remuneration family child education allowances childrens schooling costs additional remuneration abovementioned payments paid current aforementioned additional payments former members corporate executive included total remuneration members committee corporate executive committee corporate executive committees loans credits granted remuneration subject approval members corporate executive annual general meeting committee submission corporate executive maximum regular period notice members committees total aggregate bonuses corporate executive committee months binding vote annual general meeting changeofcontrol clauses board directors proposes awarding employment contracts members corporate executive committee bonuses dr severin schwan form roche remuneration former members shares blocked ten years corporate executive committee members corporate executive total chf paid dr gottlieb keller committee cash payment see totalling chf respect total remuneration paid members financial year chf excluding corporate executive committee legally required employers contributions calendar year members social security agencies submit corporate executive committee received proposed total amount ordinary annual remuneration including bonuses employer general meeting agm binding vote retrospective approvals members corporate executive committees total aggregate bonuses chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalvremuneration report roche submission corporate executive composed base pay longterm incentives committees total future aggregate ssars calculated grant value without remuneration binding shareholder vote considering reductions value due board directors proposes blocking periods applicable rsus ordinary agm approve remuneration see calculated time reservation corporate executive committee totalling nonvoting equity securities shares without chf excluding legally considering reductions value due blocking required employers contributions ahvivalv periods pension benefits excluding legally excluding bonuses period ending required employers contributions ahvivalv ordinary agm well contributions expenses payments foreign tax obligations tax consulting amount corporate executive services roche connect committees total future aggregate remuneration prospective approvals members corporate executive committees total future aggregate remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported excluding bonuses period ending remuneration shareholders ordinary agm prospectively approved remuneration members corporate executive comparison ordinary agm committee ordinary agm remuneration amounted ordinary agm approved remuneration chf excluding legally required corporate executive committee totalling employers contributions ahvivalv chf excluding legally excluding bonuses required employers contributions ahvivalv prospectively approved total remuneration members corporate executive committee comparison actual total remuneration effected chf amount period amount period amount period agm agm agm agm agm agm maximum total remuneration prospectively approved agm actual total remuneration realised total remuneration calculated end calculation end corresponding agmagm period period agm agm within approved limit calculation end period agm agm yes yes additional amount paid new members corporate executive committee approval agm within approved total amount excluding legally required employers contributions ahvivalv excluding bonuses clawback according ssars plan rules serious addition applicable statutory provisions misconduct participant may include roches longterm incentive plans include option inter alia partially reclaim distributed compensation result special circumstances clawback activity leading serious disciplinary action repeated willful failure perform duties employee voluntarily serves notice reasonably assigned roche termination employment ssars see violation law public regulation rsus see unvested date commission crime termination employment lapse immediately gross negligence willful misconduct without compensation employment engaging conduct bringing disgrace upon termination employment result disrepute roche andor subsidiaries serious misconduct ssars rsus granted violation roches directives outstanding whether vested unvested guidelines relating business conduct shall lapse immediately without compensationremuneration report roche guidelines security holdings end retain holdings board directors decided long serve corporate executive ceo roche group members committee exception bill anderson corporate executive committee must acquire dr thomas schinecker joined shares andor nes equivalent two annual corporate executive committee base salaries ceo roche group since must fulfil requirement end equivalent five annual base salaries members corporate one annual base salary respectively executive committee fulfil requirement type security value acquired ceo roche group shares andor nes annual base salary members corporate executive committee shares andor nes annual base salary security holdings associated held securities shown december december following tables shares nonvoting respectively members corporate equity securities nes ssars restricted executive committee persons closely stock units rsus shares nonvoting equity securities nes december december close relatives close relatives shares nes security holdings shares nes security holdings number number numbertype number number numbertype corporate executive committee shares nes shares nes schwan b anderson hippe schinecker c wilbur total ssars number ssars held december corporate executive committee schwan b anderson hippe schinecker ca wilbur total price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options values according corresponding annual reports restricted stock units rsus number rsus held december corporate executive committee schwan b anderson hippe schinecker c wilbur total grant value per rsu chf chf chf nes closing price grant date nes closing price grant date nes closing price grant date march march march statutory auditors report roche general meeting roche holding ltd basel audited accompanying assurance whether remuneration remuneration report roche holding ltd report complies swiss law articles year ended december ordinance audit limited information according articles ordinance audit involves performing procedures excessive compensation listed jointstock obtain audit evidence disclosures made companies ordinance contained remuneration report regard sections marked audited grey compensation loans credits accordance line including respective footnotes articles ordinance pages remuneration report procedures selected depend auditors judgement including assessment risks responsibility board directors material misstatements remuneration board directors responsible report whether due fraud error audit preparation overall fair presentation also includes evaluating reasonableness remuneration report accordance methods applied value components swiss law ordinance board remuneration well assessing overall directors also responsible designing presentation remuneration report remuneration system defining individual remuneration packages believe audit evidence obtained sufficient appropriate provide auditors responsibility basis opinion responsibility express opinion accompanying remuneration report opinion conducted audit accordance swiss opinion remuneration report auditing standards standards require year ended december roche comply ethical requirements holding ltd complies swiss law articles plan perform audit obtain reasonable ordinance kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel february kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved independent limited assurance report nonfinancial reporting corporate governance sustainability committee roche holding ltd basel engaged corporate key figures relation contributions governance sustainability committee switzerland disclosed perform assurance procedures provide limited report assurance nonfinancial reporting roche holding ltd consolidated subsidiaries criteria roche year ended december specified nonfinancial information disclosed annual report report prepared corporate governance prepared accordance suitable sustainability committee roche based criteria selected roche following criteria suitable criteria roche materiality determination process scope subject matter group level based gri standards assurance engagement relates limited published october global level assurance specified nonfinancial reporting initiative gri information year ended december roche group internal nonfinancial reporting disclosed annual report guidelines based responsible care health safety environmental protection following specified data information reporting guidelines published european published report within scope chemical industry council cefic gri limited assurance engagement standards published october materiality determination process roche global reporting initiative gri group level according requirements defined guidelines safety security gri standards disclosed pages health environmental people report contributions key figures sustainability design sustainability risks risks opportunities internally gathered opportunities determination process based collated aggregated group level activities disclosed roche group guideline grants donations paragraph risk management report sponsorship gsd data collection process correctness following consolidated disclosed website httpswwwrochecom key figures damjcrfffeadbaccaddbcc people key figures graphs engrantsdonationssponsorshipprocesspdf report published january safety security health environmental protection key figures including inherent limitations greenhouse gas emissions scope accuracy completeness specified scope resulting business flights nonfinancial information subject inherent tables graphs pages limitations given nature methods report determining calculating estimating data pricewaterhousecoopers ag birchstrasse postfach ch zurich telephone telefax wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecoopers network firms separate independent legal entityindependent limited assurance report roche addition ghg quantification subject pricewaterhousecoopers ag applies international inherent uncertainty incomplete standard quality control accordingly scientific knowledge used determine emission maintains comprehensive system quality factors values needed combine control including documented policies emissions different gases assurance procedures regarding compliance ethical report therefore read connection requirements professional standards publicly available individual roche applicable legal regulatory requirements group guidelines used roche definitions procedures well thirdparty practitioners responsibility guidelines used present specified responsibility perform assurance nonfinancial information performance engagement express limited assurance conclusion specified nonfinancial responsibility corporate governance information roche report sustainability committee conducted engagement accordance corporate governance sustainability international standard assurance engagements committee roche holding ltd responsible isae revised assurance engagements selection application suitable audits reviews historical financial criteria well preparation information respect greenhouse gas presentation specified nonfinancial emissions international standard information accordance suitable assurance engagements isae assurance criteria responsibility includes adequate engagements greenhouse gas statements record keeping well design issued international auditing implementation maintenance internal assurance standards board standards control system determined necessary require plan perform procedures enable preparation specified obtain limited assurance whether nonfinancial information free specified nonfinancial information prepared material misstatement whether due fraud material aspects accordance error suitable criteria independence quality control based risk materiality considerations independent roche holding ltd performed procedures obtain sufficient accordance international code appropriate assurance evidence procedures ethics professional accountants including selected depend assurance practitioners international independence standards issued judgement limited assurance engagement international ethics standards board isae revised substantially less accountants iesba code fulfilled scope reasonable assurance engagement ethical responsibilities accordance relation risk assessment procedures iesba code founded fundamental including understanding internal control principles integrity objectivity professional procedures performed response competence due care confidentiality assessed risks consequently nature timing professional behaviour extent procedures gathering sufficient appropriate evidence deliberately limited reviewing principles roche relative reasonable assurance engagement materiality process providing definition therefore less assurance obtained development adherence gris limited assurance engagement environmental social economic reporting reasonable assurance engagement requirements addressing soundness identification process determination performed following assurance procedures impacted stakeholders peer competition among others review integration relevant regulatory r eview application roche group requirements integration key organisational guidelines values objectives report prioritisation reviewing application roche group material aspects nonfinancial reporting contributions inspecting integration sustainability guidelines risks opportunities group risk ite visits management inquiry management process adherence remotely visiting selected pharmaceuticals suitable criteria diagnostics sites usa china ssessment processes data taiwan uk selection based consolidation quantitative qualitative criteria reviewing management nonfinancial interviewing personnel responsible internal reporting processes people nonfinancial reporting data collection contributions key figures sites visited group level assessing aggregation process data determine understanding application group level roches nonfinancial contributions guidelines believe evidence obtained ssessment key figures sufficient appropriate provide basis performing tests sample basis evidence conclusion supporting selected contributions people key figures eg roche accident conclusion rate energy consumption emissions based procedures performed air water usage discharge number evidence obtained nothing come employees fulltime equivalents percentage attention causes us believe women total workforce concerning material respects related completeness accuracy adequacy specified nonfinancial information consistency report roche holding ltd year ended r eview documentation analysis december following applies relevant policies principles materiality determination process group reviewing relevant documentation sample level disclosed pages basis including roche group nonfinancial report comply principles reporting policies management reporting gri standards structures documentation pricewaterhousecoopers ag birchstrasse postfach ch zurich telephone telefax wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecoopers network firms separate independent legal entityindependent limited assurance report roche design sustainability risks corporate governance sustainability opportunities determination process group committee roche holding ltd work level inconsistent information report disclosed paragraph risk management report pricewaterhousecoopers ag specified nonfinancial information mentioned subject matter section published report roche holding ltd correct accordance suitable criteria christophe bourgoin annina binder restriction use purpose report zurich february report prepared corporate governance sustainability committee roche holding ltd solely purpose reporting specified nonfinancial information report purpose giving conclusion accept assume responsibility legal otherwise accept liability connection purpose report including conclusion may used person report shown whose hands may come persons shall entitled rely conclusion permit disclosure report full combination suitable criteria enable corporate governance maintenance integrity roche holding ltds sustainability committee roche holding ltd website content responsibility demonstrate discharged corporate governance sustainability committee governance responsibilities commissioning work carried assurance provider independent assurance report specified involve consideration maintenance nonfinancial information without assuming integrity roche holding ltds website accordingly accepting responsibility liability assurance provider accepts responsibility third parties part fullest extent changes may occurred specified permitted law accept assume nonfinancial information suitable criteria since responsibility anyone initially presented website published f hoffmannla roche ltd group communications basel switzerland tel wwwrochecom key dates orderdownload publications internet wwwrochecompublications annual general meeting email baselwarehouseservicesrochecom march fax firstquarter sales media relations april tel email mediarelationsrochecom halfyear results july investor relations tel ninemonth sales email investorrelationsrochecom october corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement regarding forward trademarks legally protected looking statements annual report contains certain forwardlooking links thirdparty pages provided statements forwardlooking statements may convenience express opinion identified words believes expects content thirdparty pages expressly anticipates projects intends seeks disclaim liability thirdparty information estimates future similar expressions use thereof discussion among things strategy goals plans intentions various factors may cause roche annual report published german actual results differ materially future english reflected forwardlooking statements contained annual report pricing reporting consists actual annual report product initiatives competitors legislative finance report contains regulatory developments economic annual financial statements consolidated conditions delay inability obtaining financial statements regards content regulatory approvals bringing products market management report per articles fluctuations currency exchange rates incorporation consists aforementioned general financial market conditions uncertainties reports exception remuneration discovery development marketing new report products new uses existing products including without limitation negative results clinical trials printed nonchlorine bleached research projects unexpected side effects fsccertified paper pipeline marketed products increased government pricing pressures interruptions production loss inability obtain adequate protection intellectual property rights litigation loss key executives employees adverse publicity news coverage statement regarding earnings per share growth profit forecast interpreted mean roches earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share rochef hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom